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Itch is a sensation which causes scratching response to protect skin against 
external harmful reagents. Acute itch arises in short time period after insect bites or 
allergen contact. Chronic itch happens in various skin diseases such as atopic dermatitis 
(AD) and psoriasis. Chronic itch usually continues for over six weeks and is resistant to 
commonly used anti-histamine drugs. While pain has caught an early attention due to its 
severity, the molecular mechanism of itch has not been studied in detail. Itch and pain 
share common features because they are transmitted by similar neuronal circuits. 
However, itch is a distinct somatosensation and has opposite characteristics to pain. Itch 
elicits scratching but pain causes withdrawal reflex. Interestingly, minor pain induced by 
scratching reduces itch and suppression of pain by opioid analgesics such as morphine  
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elicits itch as a side effect. Despite recent advances, our understanding about itch sensory 
mechanisms is still primitive.  
Gastrin-releasing peptide receptor (GRPR) was identified as the first itch-specific 
 receptor in the spinal cord. GRPR cell ablation by bombesin-saporin abolished general 
scratching responses to pruritogens. Because GRPR mutant mice still have remained itch 
responses, it is possible that additional itch mediators are present in the spinal GRPR 
neurons. Differential screening and pharmacological or small interfering RNA (siRNA) 
approach identified four histamine-independent (Atp2a1, Pld3, Pacsin3 and Itpr3), three 
histamine-dependent (S100a8, CALR and DSP) and one both-dependent (TRPV4) itch 
genes. Atp2a1 and Itpr3 were selected for further characterization. Atp2a1 and Itpr3 are 
involved in GRPR downstream Ca2+ signaling pathway for histamine-independent itch.  
GRPR is also expressed in peripheral tissues such as dorsal root ganglia (DRG) 
and skin in addition to the spinal cord. Gastrin-releasing peptide (GRP) intradermal (i.d.) 
injection induces dose-dependent scratching responses that are abolished in GRPR 
mutant mice. Peripheral (intraperitoneal (i.p.) and i.d.) application of GRPR antagonists 
inhibits chloroquine (CQ), GRP and allergic contact dermatitis (ACD)-induced scratching 
responses in mice. It is interesting to find peripheral GRPR functions for itch sensation 
because it will provide an alternative therapeutic route for itch by targeting peripheral 
GRPR activities rather than spinal cord GRPR. This also can circumvent potential side 
effects in central nervous system (CNS) by intrathecal (i.t.) injections. 
TRPV4 was identified as a crucial itch mediator in DRG for both histamine- 
dependent and -independent itch by siRNA screening. TRPV4 is co-expressed with  
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multiple pruritic genes such as GRP, transient receptor potential vanilloid 1 (TRPV1), 
mas-related G-protein coupled receptor A3 (MrgprA3) and histamine receptor 1 (H1R). 
TRPV4-/- mice showed reduced scratching responses in CQ and histamine-induced 
pruritic models. siRNA i.t. injection efficiently reduced TRPV4 expression in DRG and 
decreased both types of itch consistently. i.t. application of endogenous TRPV4 agonist, 5, 
6-epoxyeicosatrienoic acid (5, 6-EET), caused scratching responses that were 
significantly attenuated in TRPV4-/- mice. Interestingly, TRPV4-/- mice had reduced 
scratching responses in ACD mice model without affecting on skin inflammation. 
TRPV4 expression was up-regulated in ACD mice DRG suggesting that an increased 
TRPV4 activity may be responsible for the aggravated chronic itch. Ca2+ imaging with 
DRG culture further confirmed that TRPV4 activation is functionally involved in itch 
sensory transmission in peripheral neurons. TRPV4 in DRG will be a good candidate for 
treatment of ACD-related chronic itch.  
Characterization of GRPR-mediated itch mechanisms and identification of novel 
itch-specific genes will provide basic understanding about itch sensory mechanism and 
pioneering work for future itch studies such as identifying potential itch therapeutic 
targets. 
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I. GENERAL INTRODUCTION 
 
1. Itch 
Itch or pruritus is defined as an unpleasant sensation that elicits desire or reflex to 
scratch (Rothman 1941; Stander, Steinhoff et al. 2003). Itch is a defensive sensory 
mechanism protecting the skin against harmful reagents and is conserved in various 
animal species. Acute itch is commonly elicited by skin contact with pruritic agents or 
allergens, while chronic itch often accompanies pathological skin conditions such as 
atopic dermatitis (AD) or xerosis as well as systemic disorders such as liver and kidney 
disease (Nojima, Carstens et al. 2003). Chronic itch lasts longer than acute itch and is 
often resistant to treatment with anti-histamine drugs. Thus, it has been one of the major 
problems in relieving patient symptoms in itch therapy. Itch is classified into four 
categories based on clinical aspects. First, pruritoceptive itch originates in the skin due to 
inflammation, dryness, or other skin damage. This type of itch information is transmitted 
by unmyelinated C nerve fibers. Second, neuropathic itch arises because of lesions 
located at the afferent pathway. Third, neurogenic itch is defined as that which originates 
centrally without neural pathology. Fourth, psychogenic itch is found in delusional states 
such as parasitophobia (Greaves and Khalifa 2004). Although recent findings have 
provided interesting insights into itch sensation, the molecular mechanism of itch has not 
been well investigated.  
Pruritic information is known to be transmitted to the spinal cord via DRG. Spinal 
cord dorsal horn gray matter has multiple lamina layers (Fig. 1). Lamina I neurons are  
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important components of somato-sensory circuits required for relaying nociceptive, 
temperature and itch signals from the periphery to the brain (Stander, Steinhoff et al. 
2003). These neurons comprise the spinothalamic tract that transmits inputs from primary 
afferents and project to the contralateral thalamus. There is a subpopulation of 
spinothalamic neurons that are selectively excited by histamine and transmit pruriceptive 
information through a dedicated neuronal pathway. In the spinal cord of cats, histamine-
induced itch sensation was found to be relayed by a subset of lamina I neurons, which 
were insensitive to mechanical and thermal stimuli. These lamina I neurons project to the 
posterior part of the ventromedial thalamic nucleus via the spinothalamic tract, which in 
turn projects to the dorsal insular cortex (Andrew and Craig 2001).  
 
1.1. Histamine-dependent itch 
 Histamine has been studied most thoroughly among the known pruritogens. 
Tissue inflammation and allergen contacts induce mast cell degranulation and histamine 
release (Rowley and Benditt 1956). Histamine-induced itch is accompanied by a wheal, 
caused by the enhanced permeability of blood vessels, and a flare that is produced by an 
axonal reflex (Sikand, Dong et al. 2011). Histamine-induced responses are mediated by 
histamine receptors which are members of G protein-coupled receptors (GPCRs). Four 
histamine receptor subtypes (H1R-H4R) have been identified (Hill, Ganellin et al. 2002). 
H1R has been studied most extensively for itch sensation. H1R is coupled with Gαq 
proteins and activates phospholipase C (PLC) (Bakker, Timmerman et al. 2002). 
Activation of H1R increases calcium levels in cultured sensory neurons and this is  
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blocked by a PLC inhibitor, U73122 (Nicolson, Bevan et al. 2002). PLCβ3 was found to 
mediate histamine-induced Ca2+ response via H1R in sensory neurons (Han, Mancino et 
al. 2006). H1R signaling also stimulates phospholipase A2 (PLA2), lipoxygenase (LOX) 
and TRPV1 pathways resulting in neuronal excitation (Kim, Lee et al. 2004; Shim, Tak et 
al. 2007). Although H1R antagonists (anti-histamines) are widely used to alleviate itch 
symptoms, the therapeutic efficacies of anti-histamines are limited because they cannot 
attenuate several types of chronic itch such as AD and psoriasis. This raises questions 
about potential roles of the other histamine receptors or histamine-independent pathways 
for chronic itch.  
 
1.2. Histamine-independent itch 
 Although histamine is a strong pruritic agent, it is not involved in many types of 
chronic itch diseases as shown by the weak therapeutic efficacy of anti-histamines 
(Rukwied, Lischetzki et al. 2000). Two recent studies found the existence of a histamine-
independent cowage-related itch pathway in lamina I neurons of the spinal cord 
(Davidson, Zhang et al. 2007; Johanek, Meyer et al. 2007).  
 Cowhage induces robust itch-scratching responses when injected into skin. 
Mucunain, a cysteine protease in cowhage, was recently identified as a ligand for 
protease activating receptor 2 (PAR2) and 4 (PAR4) (Reddy, Iuga et al. 2008; Davidson 
and Giesler 2010). Cowhage-induced itch was not attenuated by anti-histamine 
suggesting that cowhage is a non-histaminergic pruritogen (Shelley and Arthur 1955). 
Whereas histamine activates C fibers that are mechanically insensitive, cowhage activates  
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mechanically sensitive C fibers (Schmelz, Schmidt et al. 1997; Johanek, Meyer et al. 
2007; Johanek, Meyer et al. 2008; Namer, Carr et al. 2008). Unlike histamine, cowhage-
mediated itch does not produce weal, flare and redness (Johanek, Meyer et al. 2007). i.d. 
injection of histamine induced c-Fos expression in the lamina II neurons while PAR2 
agonist, SLIGRL-NH2 caused c-Fos expression in the region located dorsal to the lamina 
II suggesting that there are distinct spinal pathways between histamine and PAR2-
mediated itch (Nakano, Andoh et al. 2008). However, a recent electrophysiological study 
has shown a functional overlap of both pathways (Akiyama, Carstens et al. 2009).  
 CQ is an anti-malaria drug that has side effects in black Africans with generalized 
pruritus (Osifo 1984). CQ-induced itch can not be treated with anti-histamines suggesting 
that CQ is a histamine-independent pruritogen (Inan and Cowan 2004; Green, Young et 
al. 2006). i.d. injection of CQ causes robust scratching responses in mice. Therefore, CQ 
provides a reliable histamine-independent itch model in mice. Recent report showed that 
targeted disruption of mas-related G-protein coupled receptors (Mrgprs) gene cluster 
reduced CQ-induced itch responses but not histamine-induced itch (Liu, Tang et al. 2009). 
Mrgprs genes in mouse can be grouped into several subfamilies. MrgprAs, MrgprB5, 
MrgprC11 and MrgprD are expressed in subsets of small diameter DRG and trigeminal 
ganglia neurons (Liu, Tang et al. 2009). Among the Mrgprs family, MrgprA3 was 
identified as the crucial receptor for CQ-induced itch. MrgprA3+ DRG neurons also 
express GRP, which is a ligand of GRPR. This suggests that activation of MrgprA3 by 
CQ may cause a GRP release from peripheral DRG stimulating GRPR neurons in the 
spinal cord for itch sensation (Liu, Tang et al. 2009). MrgprA3 homologous receptor,  
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human MrgprXs are also expressed in DRG suggesting that Mrgprs may have some 
conserved roles in sensory neurons mediating itch. The proteolytically cleaved product of 
pro-enkephalin A, the bovine adrenal medulla peptide 8-22 (BAM 8-22), potently 
activates human MrgprX1 (Lembo, Grazzini et al. 2002) and induces scratching in human 
by histamine-independent manner (Sikand, Dong et al. 2011).  
Both itch and pain can be elicited by multiple mechanical and chemical stimuli  
through similar neuronal populations. Inhibition of pain pathways resulted in enhanced 
itch suggesting that pain has antagonistic effects on itch sensation (Lagerstrom, Rogoz et 
al.; D'Hoedt, Owsianik et al. 2008). Although several studies have provided critical 
components for itch pathways, the identity of neural circuit transmitting itch has yet to be 
clearly defined. Also, how itch pathways are related with pain is still unclear. Therefore, 
it will be important to find out molecular mechanisms of DRG and spinal cord-mediated 
pruritic pathways to understand overall itch sensation. 
 
1.3. Chronic itch 
Chronic itch is defined as an itch that lasts more than six weeks (Pogatzki-Zahn, 
Marziniak et al. 2008; Stander, Raap et al. 2011). Multiple causes can bring itchy 
conditions. External factors that cause a chronic itch include contact allergens and 
dryness. Internal factors can be allergies from food ingestion as well as infectious 
conditions such as psoriasis. Genetic factors also can be involved in chronic itch diseases 
such as AD.  
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1.3.1. Atopic dermatitis (AD) 
AD is a pruritic inflammatory skin disease associated with a personal or familial 
allergic history. About 17% of people in USA have AD and its onset is increasing 
(Laughter, Istvan et al. 2000). The skin lesion in AD results from a defective skin barrier 
that induces dry itchy skin, and is aggravated by mechanical injury due to continuous 
scratching. This allows antigens to enter via the skin and causes immune responses. 
Alternatively, the inherited primary abnormality in the immune system can causes a 
secondary defect in skin barrier function (Oyoshi, He et al. 2009). AD has no known cure 
and the condition becomes worse as the itching continues. Thus, it will be important to 
prevent the continuous scratching in AD to relieve the chronic itch symptoms.  
 
1.3.2. Contact dermatitis (CD) 
CD is an inflammatory skin condition induced by exposure to an environmental 
agent. Contact allergens are non-protein chemicals named haptens with small molecular 
weight (Gunther, Hempel et al. 2007). There are two major types of CD, irritant CD 
(ICD) and allergic CD (ACD). ICD is a pro-inflammatory response due to toxic effects of 
reagents activating skin innate immunity. ACD requires antigen-specific acquired 
immunity with T cell causing skin inflammation (Nosbaum, Vocanson et al. 2009). The 
development of ACD has two distinct steps. Sensitization (Induction) phase occurs at the 
first contact of skin with haptens and generates antigen-specific T cells in the lymph node 
(LN). The sensitization step lasts for 10-15 days in man, and 5-7 days in mouse. This step 
has no clinical relevance. Repeated exposure to the same haptens leads to the elicitation  
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(challenge) phase. Specific T cells are activated in the dermis and trigger inflammatory  
process responsible for the skin lesions. This step takes 72 hours in man, and 24-48 hours 
in mouse (Saint-Mezard, Rosieres et al. 2004). CD is closely related with our daily life 
because common causes of ACD include metals (e.g., nickel), cosmetics, drugs and 
plants (poison ivy and oak) (Krasteva, Kehren et al. 1999). 
 
1.3.3. Dry skin (Xerosis) 
Dry skin is caused by disrupting skin barrier function in stratum corneum, 
reducing water-holding capacity. Xerosis is most common in elderly people because of 
decreases in skin vascular supply and changes in epidermal lipid composition. However, 
it can be caused by drugs and environmental factors. Frequent use of soaps, detergents, 
and irritant topicals such as alcohol and hot water can induce dry skin itch. Extremely 
cold dry weather during winter season and rapid shift from dry environment to humid 
conditions also cause skin dryness and itch (Yosipovitch 2004). The mechanism of dry 
skin pruritus is still unclear and effective treatments for the pruritus have not been 
established. 
 Our knowledge about chronic itch is still in its infancy. Causes and therapies of 
most chronic itch diseases are unknown. It is important to know what makes the itch 
become chronic because it will be helpful in the development of treatments. Millions of 
people are suffering from intractable itch currently and it is necessary to uncover 
molecular pathways that are involved in chronic itch. This will provide a primary clue to 
solve the medical problems associated with chronic itch diseases.  
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2. Bombesin/GRP and GRPR 
 
2.1. Bombesin and GRP 
 Bombesin is a tetradecapeptide originally isolated from frog skin. It induces dose-
dependent long-lasting scratching when administered intracerebroventricularly (i.c.v.) to 
rats (Gmerek and Cowan 1983). Pruritus induced by bombesin is not antagonized by anti- 
histamines or opioid antagonists (naloxone) but relieved by opioid analgesics of the 
benzomorphan class, which suggests an association with the opioid system (Stander, 
Steinhoff et al. 2003). GRP was the first identified mammalian bombesin-like peptide. 
The second mammalian bombesin-like peptide, neuromedin B (NMB) was purified from 
porcine spinal cord (Minamino, Kangawa et al. 1983). GRP and NMB have been found 
in birds, fish, reptiles and mammals, suggesting some conserved functions of bombesin-
like peptides among the various animal species. GRP and NMB are expressed in the brain 
and gastrointestinal tissues, and they mediate a variety of physiological functions 
including thermoregulation, metabolic regulation and gastric secretion (Ganter and Pittet 
2006).  
 GRP is expressed in a subset of small and medium-sized DRG neurons. GRP is 
co-localized with peptidergic markers, calcitonin gene-related peptide (CGRP) and 
substance P (SP), but not with isolectin B4 (IB4), a nonpeptidergic marker, and 
neurofilament 200 (NF200), myelinated marker showing that GRP is expressed in 
peptidergic unmyelinated DRG neurons. Approximately, 80% of GRP neurons co-
express TRPV1, which is an important channel for detecting thermal and chemical  
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stimuli in DRG. In the spinal cord, GRP afferent fibers are restricted to the lamina I and  
II outer layers (Sun and Chen 2007). 
 
2.2. GRPR 
 GRPR is a mammalian homologue of the amphibian bombesin-like peptide 
receptor, and it has been implicated in various physiological processes and behaviors, 
including food intake and fear memory (Battey and Wada 1991; Roesler, Henriques et al. 
2006). GRPR is a seven trans-membrane Gαq-protein coupled receptor and activation of 
GRPR increases intracellular Ca2+ through PLC/inositol-1, 4, 5-triphosphate (IP3) 
pathway (Ally, Ives et al. 2003). GRPR was identified as the first itch-mediating receptor 
in the spinal cord (Sun and Chen 2007). GRPR mutant mice showed significantly reduced 
scratching responses in compound 48/80, PAR2 agonist (SLIGRL-NH2) and CQ-induced 
itch models (Sun and Chen 2007). Compound 48/80 degranulates mast cells and causes 
histamine release (Kuraishi, Nagasawa et al. 1995). PAR2 agonist (SLIGRL-NH2) is a 
histamine-independent itch mediator (Steinhoff, Neisius et al. 2003; Shimada, Shimada et 
al. 2006). CQ causes scratching by the histamine-independent pathway because anti-
histamine could not inhibit the response (Inan and Cowan 2004; Green, Young et al. 
2006). The fact that histamine-induced response and pain behaviors were not changed in 
GRPR mutant mice (Sun, Zhao et al. 2009) strongly suggests that GRPR is a histamine-
independent itch receptor and also strengthen the idea that there are itch-dedicated 
molecular pathways in the spinal cord.  
 Although the GRPR mutant mice scratch less in the itch models, the scratching  
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response was not completely lost. The remaining scratching behaviors of GRPR mutant  
mice indicate that there are additional itch genes in the spinal cord. It is very interesting 
and critical to identify other itch-specific molecules which will help us to uncover 
mechanisms underlying itch sensation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10
 
II. Identification of novel itch genes in the mouse spinal cord GRPR neurons 
     ; Roles of Atp2a1 and Itpr3 in GRPR-mediated itch signaling pathways 
 
INTRODUCTION 
 
1. Ablation of GRPR cells in the spinal cord by bombesin-saporin            
 GRPR mutant mice showed significantly reduced scratching behaviors caused by 
CQ suggesting that GRPR is a histamine-independent itch receptor. However, roles of the 
spinal GRPR+ cells in itch transmission have not been addressed. To study GRPR 
expressing neuronal functions, GRPR ligand, bombesin attached to saporin toxin was 
used to ablate GRPR cells in the spinal cord.                                                                           
 Saporin is a toxic protein that is useful in biological research applications. It is a 
ribosome-inactivating protein (RIP) from the seeds of Saponaria officinalis (common 
name: soapwort). Its N-glycosidase activity inactivates the ribosomes, shutting down 
protein synthesis and resulting in cell death. The enzymatic activity of the saporin is 
highly specific. It removes a single adenine base from the ribosomal RNA in the large 
subunit of the ribosome, which completely blocks the ribosome to participate in protein 
synthesis (Stirpe, Gasperi-Campani et al. 1983). Attachment of the saporin to ligands 
enables the toxin to enter specific types of cells through its cell surface receptor, which 
allows to remove certain cell types in vivo. Saporin conjugates such as SP-saporin and 
IB4-saporin already have been used successfully to deplete spinal cord lamina I and II 
neurons selectively (Mantyh, Rogers et al. 1997; Vulchanova, Olson et al. 2001). After  
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bombesin-saporin binding, GRPR will be internalized by endocytotic pathways. The 
internalized saporin will inhibit protein synthesis causing cell death (Fig. 2). Specific 
depletion of GRPR expressing neurons provided an experimental tool to allow whole 
genome differential screening to identify itch specific genes in the spinal cord GRPR 
expressing neurons. 
 
2. Differential screening to identify novel itch genes in GRPR neurons of the spinal 
cord 
GRPR mutant mice showed reduced histamine-independent itch behaviors and 
GRPR cell depletion in the spinal cord by bombesin-saporin abolished scratching 
responses to a range of pruritic stimuli (Sun and Chen 2007; Sun, Zhao et al. 2009). 
These results suggest that GRPR mediates histamine-independent itch and GRPR neurons 
are critical for general itch sensation. It is also important that GRPR cell-depleted mice 
did not change pain behaviors strongly suggesting that GRPR cells are itch-specific 
neurons (Sun, Zhao et al. 2009). Because GRPR mutant mice still showed scratching 
responses to both histamine-dependent and -independent pruritic stimuli, it is possible 
that other itch mediators are also present in the GRPR expressing cells. To identify novel 
itch genes such as additional itch receptors or GRPR downstream signaling molecules in 
the GRPR neurons, differential screening experiment was designed with blank- and 
bombesin-saporin injected mice spinal cord. For the differential screening, mice were i.t.  
injected with blank- and bombesin-saporin and GRPR cell ablation was confirmed by 
scratching responses to pruritogens, in situ hybridization (ISH) and quantitative reverse  
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transcription-polymerase chain reaction (QRT-PCR) (Fig. 2). Superficial layers of dorsal 
spinal cord were dissected by laser capture microscope (LCM). Because GRPR is 
expressed in a small subset of lamina I neurons, dissection of the restricted regions with 
GRPR cells has an advantage to reduce background or misleading results from genes 
which have differential expression levels in the other spinal cord regions (Fig. 3). DNA 
microarray was performed using illumina bead array. ISH, immunostaining and QRT-
PCR were used to verify candidate genes. Functional studies of the candidate itch genes 
were performed using pharmacological and siRNA approaches. Four histamine-
independent (Atp2a1, Pld3, Pacsin3 and Itpr3), three histamine-dependent (S100a8, 
CALR and DSP) and one both dependent (TRPV4) genes were identified. These will 
provide further understanding about itch signaling mechanisms and potential therapeutic 
targets. 
 
RESULTS 
 
1. Microarray data analysis 
When all the three blank- and bombesin-saporin treated samples were combined 
together, analysis of variance (ANOVA) test using Partek Genome Suite (Partek 
Incorporated, St. Louis, MO) did not show candidate genes that were changed 
significantly in all the bombesin-saporin treated samples. Therefore, alternative data  
analysis strategy was used. Because the samples were not prepared at the same time and 
also from different bombesin-saporin injected animals, it was reasonable to compare each  
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group separately. With each three blank- and bombesin-saporin treated samples, nine 
pairings could be generated. GRPR expression level was consistently decreased in all the 
bombesin-saporin treated groups among the nine pairings. Fold change of gene 
expression and frequency were used to choose candidate genes that had reduced 
expression levels in the bombesin-saporin treated samples consistently. Genes that 
showed same decreases in at least two pairings were selected (Table 1). From 2,354 
genes above cut-off value (fold change: -2, frequency: 2), 123 candidate genes encoding 
receptors, channels and membrane proteins were selected. QRT-PCR was performed for 
40 potential interesting targets and 16 genes showed significant fold decreases in 
bombesin-saporin treated samples (Fig. 4). To confirm the expression of 16 genes in the 
spinal cord dorsal horn, ISH was performed. mRNA expressions of eight genes were 
detected in the spinal cord (Fig. 5). Four genes showed expression level decreases in the 
bombesin-saporin treated tissues (Fig. 6) suggesting that they may be expressed in GRPR 
neurons. 
 
2. Functional studies of candidate genes 
 
2.1. Pharmacological approach 
Although some candidate genes were expressed less in the superficial dorsal horn 
after GRPR cell ablation, it is still not conclusive whether they are involved in itch 
pathways. Because membrane proteins such as receptors and channels were chosen as  
primary candidates, it is convenient to carry out pharmacological studies with specific  
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agonists and antagonists or inhibitors to verify that they are mediating pruritus. 
 Among 16 candidates, five receptor-encoding genes, Glp2r, PKR1, P2rx4, 
Nr3c2 and Npr1, have specific agonists and Atp2a1 has specific inhibitors. Potassium  
channels, Kcnj15 and Kcnq2 have multiple inhibitors but they also block many other 
different channels. Sodium channel, Cacna1c also has inhibitors common to the others. 
The other candidate genes do not have specific agonists or inhibitors.  
 
Glucagon-like peptide 2 receptor (Glp2r) 
 i.t. injection of glucagon-like peptide 2 (GLP2) did not cause scratches in mice. Co-
injection of GLP2-GRP was also performed to examine whether GLP2 can change GRP 
i.t.-induced scratches but co-injection did not change GRP-induced scratching responses, 
either. This result suggests that Glp2r may not be involved in itch sensation. 
 
Prokineticin receptor 1 (PKR1) 
Prokineticin 1 and 2 (PK1 and PK2) peptides were injected intrathecally. Both 
PK1 and 2 caused grooming, biting and licking behaviors consistent with the previous 
report that PKR1 mediates pain (Negri, Lattanzi et al. 2006; Negri, Lattanzi et al. 2009). 
However, no scratching response was detected. 
 
Purinergic receptor P2X, ligand-gated ion channel 4 (P2rx4) 
P2 purinoceptor agonist, ATP was injected into mouse spinal cord to examine 
whether P2rx4 is involved in itch sensation.  However, it did not induce scratches. 
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Nuclear receptor subfamily 3, group C, member 2 (Nr3c2) 
 Nr3c2 synthetic activator, Fludrocortisone i.t. injections did not cause scratchings.  
Fludrocortisone-GRP co-injection also did not show significant difference from GRP i.t.- 
induced scratching responses.  
 
Natriuretic peptide receptor 1 (Npr1) 
 Npr1 agonist, brain natriuretic peptide (BNP) was injected intrathecally. BNP did not 
cause scratching responses.  
 
ATPase, Ca2+ transporting, cardiac muscle, fast twitch 1 (Atp2a1) 
 Atp2a1 inhibitors, 2, 5-Di-tert-butylhydroquinone (DBHQ) and thapsigargin (TG) 
were tested with several itch models. DBHQ and TG i.t. injection inhibited GRP i.t. and 
CQ-induced scratches without changing histamine responses, suggesting that Atp2a1 may 
be involved in histamine-independent itch pathways (Figure 7).  
 
2.2. siRNA screening 
Most of the candidate genes do not have specific agonists or antagonists. siRNA 
gene knockdown approaches provide an alternative efficient method to study certain gene 
functions. If agonist or antagonist also affects other off-targets, it will mask the effects 
from the specific gene. siRNA can be used to overcome potential problems of 
pharmacological tests such as specificity issues. Previous pharmacological studies  
identified an interesting gene, Atp2a1, which is expressed on endoplasmic reticulum (ER)  
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membrane and regulates intracellular Ca2+ concentration. This suggests that GRPR 
functions can be mediated by ER Ca2+ signaling pathways. It is also consistent with the  
previous reports that GRPR activates PLC-IP3 signaling pathways (Ally, Ives et al. 2003). 
Therefore, 30 ER Ca2+-related molecules were further examined as candidates from the 
microarray gene list (Table 2). QRT-PCR confirmed that 12 genes were reduced in  
bombesin-saporin treated spinal cord (Table 3). Additional 11 ER Ca2+-related candidate  
genes were also selected for siRNA screening (Table 4).  
 
2.2.1. Histamine-independent genes: Atp2a1, Pld3, Pacsin3, Itpr3 
 
(1) Atp2a1  
 Atp2a1 encodes a sarco/endoplasmic reticulum Ca2+-ATPase (SERCA1). 
SERCA on ER membrane plays roles to maintain internal Ca2+ levels that are important 
for multiple signaling pathways requiring intracellular Ca2+ responses (Berridge, 
Bootman et al. 2003). GRPR is a Gαq protein-coupled receptor and activates PLC/IP3 
signaling pathways (Ally, Ives et al. 2003). IP3 produced by PLC binds to IP3 receptor on 
ER membrane and release Ca2+ ion from ER to increase intracellular Ca2+ concentration. 
Increased Ca2+ levels can activates multiple downstream signaling mediators and 
effectors responding to extracellular stimuli. GRPR-mediated downstream signaling 
mechanisms for itch sensation have not been studied well previously. Therefore, Atp2a1 
was chosen from the candidate genes to investigate how GRPR-mediated itch signaling is 
transmitted in cellular and molecular levels. 
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 Atp2a1 siRNA showed inhibitory effects on CQ-induced itch but not on histamine 
model (Figure 8a). This result confirms that the previous pharmacological DBHQ and  
TG data were specific to Atp2a1. ISH showed that Atp2a1 mRNA expression was 
reduced in the Atp2a1 siRNA treated spinal cord (Fig. 8d). This was confirmed again by 
QRT-PCR with spinal cord dorsal horn total RNA (Fig. 8c). i.t. application of siRNA 
affects both spinal cord and DRG gene expression (Kawasaki, Xu et al. 2008; Liu, Bi et  
al. 2010; Vergnolle, Cenac et al. 2010). Atp2a1 siRNA also reduced Atp2a1 expression  
in DRG (Fig. 8c and 9h). Although siRNA knockdown effect was high in the spinal cord, 
it is also possible that Atp2a1 in DRG may have some roles for itch sensation.  
 Atp2a gene has three different isoforms (Atp2a1, 2, 3) and each isoform 
expression was examined by ISH and QRT-PCR. Atp2a1 and Atp2a2 are expressed in the 
spinal cord and DRG. Atp2a3 expressions were detected only in the cerebellum granular 
cells (Fig. 9). Atp2a1 is the most abundantly expressed isoform in the spinal cord dorsal 
horn. Atp2a2 gene expression was found mostly in the ventral horn regions. Also, Atp2a1 
is the most affected gene in the bombesin-saporin treated spinal cord suggesting that 
Atp2a1 is expressed in the GRPR neurons and may have functional roles in GRPR-
mediated downstream signaling pathways for itch (Fig. 9). To examine the possible 
involvement of Atp2a2 for itch, Atp2a2 siRNA experiment was also performed. Atp2a2 
siRNA i.t. injection neither change CQ nor histamine itch models suggesting that Atp2a1 
is the major Atp2a isoform mediating histamine-independent itch in the spinal cord (Fig. 
8b).  
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 Atp2a1 was co-localized with GRPR in the spinal cord dorsal horn and DRG  
(88%, 84/96) (Fig. 10). Atp2a1 is co-expressed with CGRP (30%, 37/122), IB4 (29%, 
90/306), NF200 (26%, 51/195), MrgprA3 (5%, 22/426) and TRPV1 (31%, 36/115) in  
DRG (Fig. 11). Co-localization of Atp2a1 with a CQ receptor, MrgprA3 and the channel 
involved with histamine-induced itch, TRPV1 in DRG supports potential roles of Atp2a1 
in DRG for itch transmission. To examine whether Atp2a1 is involved in GRPR 
downstream Ca2+ signaling pathways, heterologous cell culture system was used. Stable  
GRPR expressing human embryonic kidney (HEK) cells showed intracellular Ca2+  
increases by GRP applications (Fig. 12a). Atp2a1 inhibitor, DBHQ pre-treatment 
releases Ca2+ from ER and depletes the internal Ca2+ store. Therefore, GRP-induced Ca2+ 
response was reduced after DBHQ treatment (Fig. 12b). However, DBHQ did not abolish 
the GRP-induced Ca2+ response completely indicating that GRPR activation also causes 
Ca2+ influx from extracellular space through plasma membrane channels. GRP response 
in GRPR HEK cells was significantly reduced after GRPR or Atp2a1 siRNA transfection 
(Fig 12 c, d). All these data suggest that Atp2a1 is involved in GRPR downstream Ca2+ 
signaling, which is important for CQ-induced histamine-independent itch sensation. 
 From 30 ER Ca2+-ATPase related molecules, 7 candidate genes were further 
identified by siRNA screening (Fig. 13). 
 
(2) Phospholipase D family, member 3 (Pld3)  
 i.t. treatment of Pld3 siRNA inhibited CQ-induced scratches but not histamine-
induced ones (Fig. 14a). siRNA specificity was confirmed by ISH and QRT-PCR. Pld3  
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siRNA reduced Pld3 mRNA levels only in the spinal cord dorsal horn but not in the DRG  
(Fig.14b-d). RT-PCR with LCM-dissected spinal cord dorsal horn superficial layers 
showed that Pld3 is the major isoform expressed in the spinal cord dorsal horn among six 
Pld isoforms (Fig.14f). Pld3 and GRP were co-localized both in the spinal cord and DRG 
suggesting that Pld3 may have potential roles in GRP-mediated itch pathways (Fig.14e). 
 
(3) Protein kinase C and casein kinase substrate in neurons 3 (Pacsin3)  
 i.t. injection of Pacsin3 siRNA decreased CQ itch (Fig 15a) and this effect was 
from Pacsin3 knockdown in the spinal cord as well as DRG based on QRT-PCR results  
(Fig. 15b). Pacsin3 is co-localized with GRP in the DRG (Fig.15c) but it is still unknown 
whether there is any functional relationship between Pacsin3 and GRP. Pacsin3 is known 
to bind and regulate TRPV4 activities (D'Hoedt, Owsianik et al. 2008). It will be 
interesting to study relationships between Pacsin3 and TRPV4 in DRG for itch 
transmission because TRPV4 was also identified as a candidate itch mediating channel 
from siRNA screening. 
 
(4) IP3 receptor, type 3 (Itpr3)  
There are three different Itpr genes, Itpr1, 2 and 3. Itpr3 was the most 
significantly reduced gene in the bombesin-saporin treated spinal cord (Fig. 16a). Itpr3 
siRNA reduced CQ itch due to spinal cord knockdown (Fig.16b-d). Atp2a1 and Itpr3 are 
important in ER Ca2+-mediated signaling pathways. Their functional involvement only in 
histamine-independent itch strongly suggests that histamine itch may have different  
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signaling mechanisms from histamine-independent itch mediated by GRPR (Fig. 17).  
Consistently, there is a recent report that histamine itch is mediated by extracellular Ca2+ 
influx through TRPV1 which is independent of ER Ca2+ pathways (Shim, Tak et al. 
2007) (Fig. 38).  
 
2.2.2. Histamine-dependent genes: S100a8, CALR, DSP 
 
(1) Calcium-binding protein A8 (Calgranulin A; S100a8)  
 i.t. injection of S100a8 siRNA decreased histamine itch. However, there was no 
difference in CQ itch after the siRNA (Fig. 18a) suggesting that S100a8 is involved in  
histamine-dependent itch pathways. S100a8 may function in the spinal cord because the  
siRNA reduced spinal cord S100a8 expression (Fig.18b).  
 
(2) Calreticulin (CALR)  
 CALR is also a calcium binding protein in ER. CALR siRNA i.t. injection 
reduced histamine itch but not CQ-induced scratches (Fig.19a). CALR may be involved 
in histamine-dependent itch pathways in the spinal cord (Fig. 19b). However, CALR 
expression was also detected in DRG and co-expressed with GRP both in the spinal cord 
and DRG (Fig. 19c, d). This raises a possibility that CALR may be involved in 
histamine-dependent pathway in GRP expressing DRG neurons.  
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(3) Desmoplakin (DSP)  
Desmoplakin is an extracellular matrix protein. i.t. treatment of DSP siRNA  
decreased histamine itch (Fig. 20a). The siRNA effects were resulted from spinal cord 
DSP knockdown (Fig. 20b). Previous studies have suggested that extracellular matrix 
proteins are involved in Ca2+ influx (Schwartz, Brown et al. 1993; Bixby, Grunwald et al. 
1994). Therefore, it is possible that DSP is involved in extracellular Ca2+-mediated itch 
signaling pathways for histamine itch in the spinal cord.  
 
2.2.3. Both-dependent gene: TRPV4 
 
(1) TRP vanilloid 4 ion channel (TRPV4) 
 TRPV4 is one of TRP channels expressed in DRG. TRPV4 siRNA i.t. injection 
inhibited both CQ and histamine-induced scratches (Fig. 33b). TRPV4 is only expressed  
in DRG and not in the spinal cord (Fig. 29). QRT-PCR confirmed that siRNA reduced  
TRPV4 expression in DRG (Fig. 33c). Because TRPV4 expressing DRG neurons also 
express GRP (Fig. 30d-f and Fig. 32a-c), there is a possibility that TRPV4 may have be 
involved in GRP-mediated itch. Functional studies of TRPV4 in itch are described 
separately in the last section of this thesis.  
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DISCUSSION 
 
1. Microarray 
The reason that ANOVA analysis did not show any gene changed significantly in 
all the bombesin-saporin treated spinal cord may be sample variations. Also, the RNA  
amplification step can affect on the real gene expression levels. However, GRPR showed 
significantly reduced expression in all the bombesin-saporin treated spinal cord when 
compared each group separately, indicating that microarray data from the differential 
screening between blank- and bombesin-saporin injected mice are still valid. The primary 
targets are membrane proteins such as receptors and channels. There are also other 
candidate genes encoding signaling molecules and transcription factors. The role of 
dorsal horn inhibitory neurons expressing a transcription factor, Bhlhb5 in itch has been 
reported recently (Ross, Mardinly et al. 2010). Loss of these neurons resulted in an 
enhanced pruritus. Therefore, it will be interesting to identify additional novel itch 
signaling molecules or transcription factors that regulate itch-specific gene expressions in  
the future.  
 
2. Pharmacological approaches 
Six candidate genes from differential screening were tested with pharmacological 
approaches. However, Atp2a1 was the only gene whose inhibitors reduced GRP- and 
CQ-induced itch. The other receptor or channel genes did not show significant 
differences in itch responses with specific agonists or antagonists. However, it is  
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important to find an effective dose for chemical reagents. The effects of agonists and 
antagonists or inhibitors were tested with i.t. injections. There are possibilities that theses 
candidate genes are also expressed in the peripheral tissues and mediate itch. It will be 
interesting to examine expressions of the candidate genes in DRG and skin and test those 
chemical effects by peripheral applications such as i.p. and i.d. injections. 
 
3. siRNA screening 
It is important to notice that siRNA i.t. injection affects both spinal cord and DRG 
gene expression (Kawasaki, Xu et al. 2008; Liu, Bi et al. 2010; Vergnolle, Cenac et al. 
2010). Based on the expression patterns, the siRNA effect can be localized at either place 
or both. If the gene is expressed in the spinal cord or DRG only, the siRNA-mediated 
knockdown can identify tissue-specific roles of the candidate genes. However, when they 
are expressed in both tissues, it will be difficult to find out the tissue-specific gene 
functions. To resolve these issues, DRG and spinal cord dorsal horn cultures may be used 
with siRNA transfection to examine their responses to pruritogens by using Ca2+  
imaging or electrophysiological approaches. If tissue-specific conditional mutant mice 
are available, behavioral studies with the mutant mice will be helpful to support siRNA  
results in specific tissues. siRNA efficiency also can be affected by dose, time and  
delivery methods. It is critical to find an efficient dose and delivery method for successful 
gene knockdown. Because high concentration of siRNA and vehicle (PEI) caused strong 
pain responses in mice, several combinations have been tested as preliminary 
experiments. 2.5µg siRNA per single i.t. injection provided the most efficient knockdown  
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without causing severe pain or toxicity problems. Single injection was not enough to 
knockdown gene expression consistently, therefore siRNA was injected once daily for 
three days. 
Atp2a1 was the only target identified from the pharmacological approaches. 
Additional Atp2a1-related Ca2+ signaling molecules were selected for siRNA screenings 
to find more itch candidate genes. Although the other genes except Atp2a1 did not show  
significant changes in scratching responses with agonist or antagonist, it will be worth 
while to confirm them with siRNA knockdown again. Although siRNA is a useful tool to 
knockdown gene expressions, it may not abolish mRNA levels completely. Partial 
knockdown could be the potential problem of siRNA approach. Single approach seems 
not to be sufficient to identify gene functions in itch sensation. Combinatorial studies 
with siRNA and mutant mice or heterologous cell culture system will resolve the 
weakness of single siRNA experiment.  
 
4. Atp2a1 and Itpr3 
Atp2a1 and Itpr3 were identified as Ca2+ signaling molecules in GRPR 
downstream signaling pathway for itch. However, histamine itch receptor, H1R is also a  
Gαq protein-coupled receptor that release Ca2+ from ER upon activation. An important  
question is why Atp2a1 and Itpr3 are only involved in histamine-independent itch. First 
explanation is that H1R is not only dependent on ER Ca2+ but also extracellular Ca2+ 
influx through TRPV1. In this case, although one pathway is inhibited, the other pathway 
still can mediate the response. Another potential answer is isoform-specific signaling  
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pathways. Histamine-dependent and -independent itch signaling may activate 
intracellular Ca2+ response by specific isoform of signaling molecules. For example, 
PLCβ3 is only involved in H1R-mediated histamine itch. This also may be applied to 
distinguish itch from pain pathways. Each pathway can be separated by distinct signaling 
pathway such as intracellular and extracellular Ca2+ influx or balanced combination of 
both. Alternatively, two pathways may use similar downstream signaling pathways but  
certain isoform of signaling molecules can be specified for each pathway. Atp2a1 and 
Itpr3 have broad expression patterns in the spinal cord and DRG. Because ER Ca2+-
mediated responses are common signaling pathways of multiple G protein-coupled 
receptors (GPCRs), extensive pain behavior studies will be necessary to examine whether 
the candidate genes are only specific to itch.   
 
MATERIALS AND METHODS 
 
Laser capture microdissection (LCM) and RNA preparation 
Three blank- and bombesin-saporin treated mice spinal cords were dissected and 
sectioned with 30μm thickness using a cryostat (Leica). Lumbar spinal cord was used for  
LCM because bombesin-saporin was injected into the region and it is also easier to  
dissect lamina I and II out from the large enlargement than the other parts of the spinal  
cord. Superficial layers including lamina I and II can be easily distinguished from the 
other regions due to its increased transparency. The tissue slides were fixed with series of 
ethanol as previously described (Gallup, Kawashima et al. 2005; Espina, Wulfkuhle et al.  
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2006). Fixed tissue slides were kept in a dry chamber with Drierite Dessicants (W.A.  
Hammond Drierite Co. Ltd) to reduce massive RNA degradations. The cervical part of 
the spinal cord was fixed with 4% paraformaldehyde (PFA) and protected with 30% 
sucrose in diethylprocarbonate (DEPC)-phosphate buffered saline (PBS) to verify 
molecular marker gene expressions. Most superficial layers of spinal cord dorsal horn 
were isolated using PixCell IIe LCM system (Molecular Devices) and captured with 
CapSure HS LCM Caps (Molecular Devices). Total RNAs were prepared from the laser  
captured tissues by using RNA Pico Isolation Kit (Molecular Devices). The qualities of 
the RNAs were assayed with Nonodrop 1000 (Thermo Scientific) and Agilent 2100 
Bioanalyzer (Agilent Technologies).  
 
Microarray and data analysis 
RNAs were amplified by WT-Ovation Pico System (NuGen) to make cDNAs. The 
quality of total cDNA was also measured with 2100 Bioanlyzer. Three pairs of cDNAs 
from blank- and bombesin-saporin treated samples were hybridized to Illumina bead 
mouse 6 array (version 2.0) simultaneously. Hybridized probe signals were scanned with 
Illumina Beadarray Reader. Raw image files were obtained with Illumina Bead Studio 
software. Partek Genomics Suite program was used for data analysis. The illumina raw  
data file was first converted to Partek file format. ANOVA statistical analysis was  
performed to compare fold changes with normalization. Three pairs of blank- and  
bombesin-saporin treated samples could generate nine comparisions. Candidate genes, 
which showed significantly decreased levels in the bombesin-saporin treated samples,  
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were selected by comparing each sample group. Multiple probe sets representing a single 
gene transcript were combined into one data point in order to reduce duplication of 
candidate genes. Ingenuity Pathways Analysis (IPA) also has been performed to find 
possible signaling pathways in which the candidate genes are involved. 
 
Quantitiative reverse transcription-polymerase chain reaction (QRT-PCR) 
cDNAs were synthesized from the blank- and bombesin-saporin treated spinal cord 
lamina I and II RNAs (from LCM dissection) using Superscript Reverse Transcriptase 
(RT) II (Invitrogen) and QRT-PCR was performed using iQ SYBR Green Supermix  
(Bio-Rad) and Mx3000P qPCR system (Stratagene). Primer sequences are shown in 
Table. 5 
 
In situ hybridization (ISH) and 3,3'-Diaminobenzidine (DAB) staining 
To amplify the gene of interest, the primers flanking about 1kb cDNA sequence were 
designed. If the gene expression patterns by ISH and probe sequences are available on the 
Allen Brain Atlas web site (Allen Institute for Brain Sciences: http://www.brain-map.org), 
the information was used to make the ISH probe. Amplified PCR fragments were sub-
cloned into pBlueScript KS vector (Stratagene) and sequenced for confirmation. Once it 
is confirmed, the sub-cloned plasmids were used as templates for synthesizing anti-sense 
RNA probes by in vitro transcription using T7, T3 or SP6 RNA polymerases (Fisher  
Scientific). Digoxigenin-labeled RNA probes were made and hybridized as previously  
described (Birren, Lo et al. 1993). For DAB staining, slides were treated with 3%  
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hydrogen peroxide (H2O2) in PBS after ISH. Slides were incubated with Rabbit anti-GRP 
antibody (Immunostar, 1:1000) in PBS/1% donkey serum/0.3% Triton X-100 at 4ºC for 
overnight. After washing twice in PBS, slides were incubated with biotinylated secondary 
antibody (Jackson ImmunoResearch, 1:200) for 2 hours at RT. Slides were washed in 
PBS and incubated with ABC mix (mix A (1:200) and B (1:200); Vectastain Elite ABC 
kit) in PBS at RT for 1hour. Slides were washed in PBS and incubated with 0.02% 
DAB/0.00003% H2O2 in PBS for color development. 
 
Pharmacological studies 
 
(1) Agonists/antagonists 
Five receptor agonists, Glucagon-like peptide 2 (GLP2, BIOMOL, 0.5-2ug), Prokineticin  
1 and 2 (PK1 and PK2, Phoenix Pharmaceuticals, 0.25-0.5μmol), P2 purinoceptor agonist, 
ATP (Tocris, 0.5-1M), Nr3c2 synthetic activator, Fludrocortisone (Sigma, 1-5ug), Brain 
Natriuretic peptide (BNP, BIOMOL, 0.5-1μg) were injected into mouse spinal cord 
intrathecally. 
 
(2) Inhibitors 
Atp2a1 inhibitors, 2, 5-Di-tert-butylhydroquinone (DBHQ, BIOMOL, 5-10μg) and 
thapsigargin (TG, BIOMOL, 5-10μg) were tested with several itch models by i.t. 
injections. 
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In vivo siRNA injection 
siRNA (Sigma) was dissolved in DEPC-treated PBS. ExGen 500 in vivo transfecting  
reagent (Polyethylenimine (PEI;0.18μl/1μg siRNA); Fermantas) was mixed to enhance  
siRNA cell penetration. siRNA solution (2.5ug siRNA-PEI mix) was injected into mice  
intrathecally once daily for three days as described (Kawasaki, Xu et al. 2008). After 30 
min of the last injection, scratching behaviors with pruritogens were monitored for 30 
min. DEPC-PBS/PEI mix was used as a control. 
 
QRT-PCR for siRNA  
Lumbar spinal cord dorsal horn and DRG were dissected out from control (DEPC- 
PBS/PEI) and siRNA-treated mice. Tissues were homozenized with Dounce glass 
homogenizer (Wheaton) and total RNA was prepared by using Trizol reagent 
(Invitrogen). cDNA was synthesized using Superscript First-strand synthesis system 
(Invitrogen) and conventional or QRT-PCR was performed using iQ SYBR Green 
Supermix (Bio-Rad) and Mx3000P qPCR system (Stratagene). Expression of target 
mRNA was normalized to 18S ribosomal RNA (rRNA) level. 
 
Double fluorescence ISH and immunohistochemistry (IHC) 
Two different (fluorescein and digoxygenin; Roche)-labeled probes were prepared. 
Fluorescein-labeled probe was purified through G50 microcolumn (Amersham-
Pharmacia) and then precipitated with lithium chloride (LiCl2). Two probes were added 
into hybridization buffer. Procedures were same as the single ISH previously described  
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(Birren, Lo et al. 1993). Fluorescent ISH combined with IHC was performed as described 
(Dong, Han et al. 2001). After ISH, Primary rabbit-GRP (Immunostar, 1:1,000) and 
TRPV1 (Chemicon; 1:1,000), guinea pig-CGRP (Peninsula, 1:1,000) and mouse-NF200 
(Sigma, 1:1,000) antibodies were used and followed by incubating with secondary 
donkey anti-rabbit or mouse-IgG coupled to FITC (Jackson ImmunoResearch, 1:400). 
IB4-FITC (Sigma, 1:200) was used to show IB4 stainings. Slides were examined using 
Olympus BX51 upright microscope attached with a CCD camera. 
 
siRNA transfection and Ca2+ imaging with GRPR-HEK cells. 
siRNA was dissolved with RNAse-free universal buffer (20mM KCl, 6mM HEPES pH 
7.5, 0.2mM MgCl2) to make 20μM stock solution. The stock solution was heated at 90ºC 
for 2 min for denaturation and cooled down to room temperature for re-annealing. The re-
annealed siRNA solution was stored at 4ºC for overnight and kept in small aliquots at -
20ºC. Stable GRPR-expressing HEK cells were cultured in Dulbecco’s modified eagle 
medium (DMEM; Gibco) with 10% fetal bovine serum (FBS; Gibco) and plated onto 
poly-ornithine-coated 12 mm diameter round glass coverslips in 24-well plate. GRPR-
HEK cells were transfected with GRPR and Atp2a1 siRNA (60 pmol) by using 
Lipofectamine 2000 reagent (Invitrogen). After 24 hours, cell culture media was replaced 
with Ca2+ imaging buffer (140nm NaCl, 4mM KCl, 2mM CaCl2, 1mM MgCl2, 5mM 
Glucose, 10mM HEPES, adjusted to pH 7.4 with NaOH). Fura-2 (Invitrogen) was diluted 
to 2mM stock in dimethylsulfoxide (DMSO)/20% Pluronic acid (Invitrogen). Cells were 
loaded with Fura-2 (2μM) diluted in the Ca2+ imaging buffer. The coverslips were  
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mounted on a Warner Instruments recording chamber (RC 26G) perfused with Ca2+ 
imaging buffer at a rate of 1ml/min. An inverted microscope (Nikon Eclipse Ti 20x 
objective) with Roper Cool SNAP HQ2 digital camera was used for Fura-2 Ca2+ imaging 
after 340nm/380nm laser excitations (sampling interval 1sec, exposure time adjusted for 
each experiment). DBHQ (50μM) and GRP (250pM) were applied to cultures to examine  
Ca2+ responses. Nikon NIS elements version 3.1 and Graph pad prism software were used  
to analyze Ca2+ imaging data.  
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III. GRPR mediates itch sensation in peripheral DRG and skin 
 
INTRODUCTION 
 
1. Skin  
 Skin is a highly complex organ innervated by a variety of specialized sensory 
neurons sensitive to heat, cold, pressure, itch and pain (Montagu 1978). It has been an 
important question whether sensory neurons are the primary transduction element, or 
whether non-neuronal cells can act as a crucial signaling pathway, with subsequent 
activation of adjacent nerve terminals resulting in a perception of touch, temperature, 
pain, or itch. Specialized epithelial structures such as hair cells, merkel cells, and taste 
buds are known to play a role in sensory transduction, but recent evidence suggests that 
other candidates such as keratinocytes may also be primary transducers of mechanical 
stimuli (Lumpkin and Caterina 2007). It is highly possible that non-neuronal cells in skin 
may function as primary transducers of certain physical or chemical stimuli and can 
communicate to neighboring sensory afferents. Because itch sensation arises in skin 
responding to extracellular pruritogens and the signal is relayed by DRG to central 
nervous system (CNS), it will be necessary to understand basic molecular mechanism of 
itch mediated by peripheral tissues.  
 
1.1. Keratinocytes 
 Keratinocytes in the epidermis proliferate from a basal layer located at the  
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dermal-epidermal boundary and form a well-organized stratified epithelium through a  
coordinated cell differentiation and migration (Lumpkin and Caterina 2007). Sensory 
receptors on epidermal keratinocytes have functional roles in permeability barrier 
homeostasis and it has been shown that TRPV1 agonists delay barrier recovery, whereas 
TRPV4 accelerates it (Denda, Sokabe et al. 2007). Keratinocytes also can be the primary 
transduction element using signal transduction such as intracellular Ca2+ influx to elicit a 
response in adjacent C-fibers (Denda, Nakatani et al. 2007). Putative keratinocyte-neuron 
interactions, intermediate molecules and second messenger-mediated signaling cascades 
have been proposed (Lumpkin and Caterina 2007). 
Several evidences suggest that keratinocytes participate in the detection of 
physical and chemical stimuli. First, at least two populations of sensory afferent fibers 
have been identified within distinct epidermal layers (Zylka, Rice et al. 2005). While 
sensory neurons that express pro-inflammatory neuropeptides, CGRP ascend through the 
basal epidermal layer to terminate in the next layer, the stratum spinosum, non-
peptidergic neurons that express a specific G-protein-coupled receptor, MrgprD, 
terminate more superficially, in the stratum granulosum. These two neuronal populations 
exhibit different projection patterns to the spinal cord and have distinct sensory functions 
(Snider and McMahon 1998). Although classical synaptic structures between 
keratinocytes and sensory nerve terminals have not been observed, the proximity of these 
cell types and close membrane apposition (Hilliges, Wang et al. 1995; Chateau and 
Misery 2004) will provide strong opportunity for rapid paracrine signaling. Second, 
keratinocytes secrete numerous chemical substances such as neurotrophins, ATP, β- 
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endorphin, interleukins and endothelin-1 that can modulate, activate or inhibit sensory  
neurons (Shu and Mendell 1999; Khodorova, Fareed et al. 2002; Koizumi, Fujishita et al. 
2004; Xu, Delling et al. 2006). Interestingly, different layers of the epidermis can release 
certain substances with different effects. Whereas superficial keratinocytes can release 
anti-nociceptive molecules such as β-endorphin, stimulation of deeper epidermal 
keratinocytes causes a secretion of pro-nociceptive endothelin-1 (Khodorova, Navarro et 
al. 2003). The existence of such potentially antagonistic systems in the epidermis 
suggests that non-neuronal skin cells are able to distinguish and process specific signals 
at the upstream of the nervous system. Third, keratinocytes express various receptors that 
have been implicated in pain or temperature sensation. However, it is difficult to 
distinguish whether the receptors facilitate signaling between keratinocytes, keratinocytes 
and neurons or both. It will be an interesting question whether non-neuronal 
keratinocytes are directly involved in itch sensory signaling pathways.  
 
1.2. Mast cells 
 As shown in a mouse model, mast cells and neuropeptides may play an important 
role in immediate hypersensitivity. During an allergic reaction, mast cells become IgE-
dependently activated (type I reaction) (Ravetch and Kinet 1991). Additionally, mast 
cells can be IgE-independently stimulated by neuropeptides such as SP mediating an 
edema after being injected intracutaneously. SP also mediates the recruitment of 
leukocytes (Goebeler, Henseleit et al. 1994), which is partially dependent on mast cell 
degranulation (Yano, Wershil et al. 1989). After peptidergic stimulation, mast cells are  
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capable of releasing not only histamine, but several other inflammatory mediators such as 
IL-6, TNF-α (Ansel, Brown et al. 1993; Goodness, Albers et al. 1997), or proteases such  
as tryptase (Corvera, Dery et al. 1997; Molino, Barnathan et al. 1997; Steinhoff, Corvera 
et al. 1999; Steinhoff, Vergnolle et al. 2000) that may contribute to neurogenic 
inflammation and itch.  
 
1.3. Cutaneous nerves 
 The axon terminals of nociceptive neurons do not possess specialized end organ 
structures and are referred to as free nerve endings for that reason. Cutaneous innervation 
consists mainly of unmyelinated fibers, accounting for around 90% of all dermal nerve 
fibers (Ebenezer, McArthur et al. 2007). Over 50% of the unmyelinated axons of a 
peripheral nerve respond not only to intense mechanical stimulation, but also to heat and 
noxious chemicals, and are therefore classified as polymodal nociceptors (Bessou and 
Perl 1969) or C-mechano-heat (CMH) nociceptors (Campbell et al. 1989). Cutaneous 
nerves are connected to DRG and projected to dorsal spinal cord. Therefore, it will be 
important to study functional roles of peripheral nerves to understand itch because they 
are the first transition point translating non-neuronal stimuli to neuronal activities.   
 
2. GRP and GRPR in skin 
GRP, a bombesin-like peptide was identified as one of the spinal cord dorsal horn 
enriched genes from dorsal vs. ventral horn differential screening (Li, Wang et al. 2006). 
Functional studies of GRP and GRPR have been focused in DRG and spinal cord,  
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respectively. However, bombesin was originally isolated from frog skin (Anastasi 1971) 
and most of itch sensations happen in the periphery. Also, GRP and GRPR are expressed  
in the peripheral tissues such as DRG and skin (Staniek, Misery et al. 1996) in addition to 
the spinal cord. This raised a question about GRP and GRPR roles in the peripheral 
region.  
 GRP i.d. injection caused dose-dependent scratching responses. The GRP i.d.-
induced scratches were abolished in GRPR mutant mice. NMBR, a GRPR homologous 
receptor is also expressed in spinal cord, DRG and skin. NMB and bombesin i.d. 
injection caused scratching responses that were completely lost in GRPR/NMBR double 
mutant mice. This suggests that bombesin-related peptides and receptors have conserved 
functional roles for itch in peripheral tissues. GRPR antagonist i.p. and i.d. injection 
inhibited CQ, GRP and NMB i.d.-induced scratchings. GRPR antagonist also attenuated 
chronic itch in ACD model mice painted with diphenylcyclopropenone (DCP). These 
results strongly support that GRP and GRPR also mediate itch sensation in the peripheral 
regions as well as the spinal cord. 
 
RESULTS 
 
1. GRP and GRPR are expressed in peripheral tissues. 
GRP expression was examined in spinal cord, DRG and skin (Fig. 21). GRP 
antibody specificity was confirmed in GRP-/- mice DRG and skin (Fig. 21d, f, h). GRP 
expression was detected in skin free nerve endings and was co-localized with peptidergic  
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CGRP+ fibers (Fig. 21g-k) consistent with the previous GRP expression results in DRG 
(Sun and Chen 2007). GRPR was also examined in both DRG and skin (Fig. 22). GRPR 
cells co-express CGRP (61%), IB4 (33%) and NF200 (14%) in DRG (Fig. 23). GRPR  
skin immunostaining showed GRPR expressions in epidermal keratinocytes and dermal 
mast cells (Fig. 22e-f) suggesting potential roles of GRPR in the periphery. GRPR+ nerve 
fibers have not been found but it requires more detail observations because DRG cells are 
expressing GRPR. Skin GRPR expression was further confirmed by RT-PCR with WT 
and GRPR mutant skin tissues (Fig. 22g).  
 
2. Peripheral GRPR is involved in itch. 
GRP i.d. injection caused dose-dependent scratching responses (Fig. 24a). 
Because GRPR positive nerves were not detected, GRP i.d. seems to activate GRPR in 
skin cells. GRPR mutant mice abolished GRP i.d. responses suggesting that GRP i.d.-
induced itch depends on GRPR (Fig. 24b-c).  
 NMBR, a GRPR homologous receptor, was also detected in the spinal cord, DRG 
and skin (Fig. 25). NMB i.d. injection causes dose-dependent scratches (Fig. 26a) like 
GRP suggesting that bombesin receptor signaling mechanisms are conserved in the skin. 
NMB i.d.-induced scratches were significantly reduced in GRPR-/- mice (Fig. 26b) 
suggesting that NMB can also bind to GRPR and activate GRPR-mediated itch signaling 
pathways. All the bombesin-like peptide (GRP, NMB and bombesin) i.d. injection caused 
scratching responses but these were completely abolished in GRPR/NMBR double 
mutant mice (Fig. 26c-e) suggesting that GRPR and NMBR are the receptors mediating  
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peripheral bombesin peptide-related itch sensations.  
 
3. Peripheral application of GRPR antagonists inhibits both acute and chronic itch. 
GRPR specific antagonists, D-Phe-Leu-bombesin and BW-10, were applied by i.p. 
and i.d. injections. These antagonists inhibited CQ, GRP and NMB i.d.-induced itch (Fig.  
27a-e) suggesting that peripheral applications of GRPR antagonists are efficient methods 
to inhibit GRPR-mediated itch. Interestingly, D-Phe-Leu bombesin i.p. injection partially 
reduced histamine-induce scratching responses (Fig. 27f). It is possible that GRPR also  
mediates histamine itch because it is also expressed in mast cells. However, it remains a 
question whether peripheral GRPR activities are involved in mast cell degranulation, 
histamine-release or histamine receptor signaling.  
To test the GRPR antagonists in chronic itch, DCP-painted ACD mouse model 
was used. DCP painting caused increase of skin epidermal thickness, hyperplasia and 
robust scratching responses (Fig. 28a-d). D-Phe-Leu-bombesin i.p. injection inhibited 
DCP-painted mice scratches suggesting that skin GRPR is also involved in chronic itch 
responses (Fig. 28e). 
 
DISCUSSION 
Previous studies have focused on the effect of GRP from afferent fibers based on 
the function of GRPR in the spinal cord. However, GRP expression both in the spinal 
cord and skin raises two additional possibilities for GRP-GRPR signaling mechanisms. 
First, although it is not known whether GRP and GRPR are expressed in the same cells  
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for autonomous signaling, GRP can be released from spinal cord neurons and activates 
closely located spinal GRPR expressing cells. Second, GRP expressions in skin free 
nerve endings suggest that GRP can be released from the peripheral nerves and stimulate 
GRPR positive skin cells such as keratinocytes and mast cells. To distinguish peripheral 
GRPR roles from central spinal cord GRPR, it will be necessary to use skin specific 
GRPR conditional mutant mice to examine itch behaviors. Activation of GRPR 
expressing skin cells may release other pruritogens to induced scratching responses. Ca2+ 
imaging with skin cell (keratinocytes) culture can support that GRPR in skin can be 
activated by peripheral GRP and mediate itch sensation. Stable fibroblast cell lines can be 
considered for Ca2+ imaging experiment, if they express GRPR endogenously.  
It will also be interesting to determine whether GRP i.d.-induced itch is 
histamine-independent by using anti-histamine because GRPR expression was examined 
in dermal mast cells. D-Phe-Leu-bombesin i.d. injection inhibited histamine-induced itch 
suggesting that GRPR in skin also can mediate histamine-dependent pathways (Fig. 27f). 
 While i.t. application of drugs or siRNA will be required to block spinal cord 
GRPR activities for itch therapy, it is inconvenient and difficult to get consistent results. 
Direct injection to the spinal cord may cause unwanted side effects in CNS. Therefore, 
identification of alternative route to inhibit itch will have great impacts on therapeutic 
approaches. Based on GRPR functions in peripheral tissues, i.p. and i.d. or topical 
applications of drugs such as GRPR antagonists can be considered to treat both acute and 
chronic itch.  
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MATERIALS AND METHODS 
 
In situ hybridization 
Lumbar spinal cord and DRG were dissected and fixed with 4% paraformaldehyde (PFA) 
for overnight. After washing with DEPC-PBS, tissues were protected with 20-30 % 
sucrose solution until they were sunk down. Tissues were embedded in OCT (Tissue-tek)  
and sectioned at 20μm by using cryostat (Leica). GRP, GRPR and NMBR ISH were 
performed as other ISH described in Chapter II. 
 
Immunostaining 
Lumbar spinal cord and DRG were processed same as in ISH procedures. Tissues were  
sectioned on Superfrost plus microscope slides (Fisher) or used for free-floating stainings. 
GRP and GRPR immunostaining in the spinal cord and DRG were performed with rabbit 
GRP (Immunostar, 1:1,000) and GRPR (MBL, 1:1,000) primary antibodies and followed 
by Cy3-conjugated anti-rabbit IgG secondary antibody (Jackson Immunoresearch, 1:400). 
 
Skin immunostaining 
Mouse neck and paw skin were dissected. Ventral paw skin was used as a glabrous skin 
and dorsal side of paw and neck skin was used as a hairy skin. Skin was fixed for 
overnight 4°C in Zamboni’s fixative (2% formaldehyde, 15% [v/v] sat. picric acid, 0.1 M 
phosphate buffer [pH 7.3]) and frozen in OCT (Tissue-tek). Skin tissue was sectioned at 
30μm and placed directly into PBS in multi-well plates for immediate staining as free- 
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floating sections. Tissue was washed in PBS for and then incubated on a horizontal 
shaker with primary antibody overnight at 4°C in incubation medium (PBS  
containing 1% normal donkey serum, 0.3% Triton X-100). Tissue was washed with PBS  
+ 0.1% Triton X-100 (PBST) and incubated with secondary antibody in the same 
incubation medium for two hours at RT. Tissue was washed with PBST. Skin tissue was 
mounted on slides and observed with fluorescent microscope.  
 
Skin RT-PCR 
Dorsal neck skin was dissected from WT and GRPR mutant mice and homogenized in 
Trizol reagent (Invitrogen) with Dounce glass homogenizer (Wheaton). Total RNA was 
prepared and used to synthesize cDNA as shown in the previous chapter. Conventional 
RT-PCR was performed with GRPR and NMBR primers. GRPR: 5’-
ACCTGAACTTGGACGTGGAC-3’ and 5’-TCAGTTTGCAGCCAATTCTG-3’, 
NMBR: 5’-ATGCCCCCCAGGTCT-3’ and 5’-TCACAGTGCTATTTC-3’ 
 
Fluorescent ISH and immunostaining 
DRG Fluorescent ISH was performed with the GRPR probe first and followed by 
immunostaining using antibodies against multiple neuronal markers such as CGRP, IB4 
and NF200. Anti-rabbit CGRP (Chemicon, 1:1,000) and NF200 (Sigma, 1:1,000) primary 
antibodies were used.  FITC-conjugated secondary rabbit antibody was used to detect the 
primary antibodies. IB4-FITC (Sigma, 1:200) was used to show IB4 staining.  
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Peripheral injection of bombesin-like peptides and GRPR antagonists 
GRP, NMB and bombesin (100nmol/50μl saline) were injected intradermally. Scratching 
responses were examined for 30 min with 5 min intervals. GRPR antagonists, D-Phe-
Leu-bombesin (Tocris, 10nmol) and BW-10 (Bachem, 10nmol) were injected 
intraperitoneally 30 min before the injection of bombesin peptides. D-Phe-Leu-bombesin 
(15nmol) was also injected intradermally 10 min before the test. 
 
DCP painting 
Diphenylcyclopropenone (DCP) was dissolved in acetone. To induce CD, mice were 
shaved on the back and sensitized by painting with 0.2 ml of DCP (1%) once on the skin  
of the neck. Seven days after the sensitization, mice were challenged by painting with 0.2 
ml of DCP (0.5%) on the same place.  
 
Skin H&E staining 
Untreated control and DCP-painted skin were dissected and fixed with 4% PFA in PBS. 
Tissue was dehydrated by ethanol and embedded in paraffin. It was sectioned at 5μm 
with microtome. Section was de-paraffinized and re-hydrated with xylene, 100%, 95%, 
80% ethanol and deionized water. Slides were stained with hematoxaline (Fisher) and de-
stained with ethanol and water. Slides were stained with eosin (Fisher) and de-hydrated 
with 95%, 100% ethanol and xylene.  Slides were covered with coverslip using Cytoseal-
XYL mounting medium (Richard-Allen Scientific).  
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IV. Role of TRPV4 in itch signaling pathways 
      ; TRPV4 mediates acute and chronic itch in peripheral DRG neurons  
 
INTRODUCTION 
 
1. TRP channels in itch 
Transient receptor potential (TRP) ion channels are expressed in sensory nerves, 
keratinocytes, and certain leukocytes. TRPs are activated by temperature, pH changes, 
and certain toxins. Recent evidences indicate that the TRP channels are crucially 
involved in pruritus, making them as good candidates for future therapeutic targets in 
skin inflammation and itch (Steinhoff and Biro 2009). 
 
1.1. TRPV1 
TRPV1 has been studied most widely among the TRP ion channel subfamily. It is 
involved in noxious heat (>43ºC) sensation and mediates thermal hyperalgesia under 
inflammatory conditions. TRPV1 can be activated by multiple extracellular stimuli such 
as noxious heat, proton and capsaicin (Caterina, Schumacher et al. 1997). TRPV1 is 
highly expressed in peripheral DRG neurons in mammals, especially in C-fiber neurons 
(Cortright, Crandall et al. 2001). Several itch mediators such as histamine, bradykinin, 
and neurotrophins activate or sensitize TRPV1 (Steinhoff, Bienenstock et al. 2006). 
TRPV1 is required for histamine itch with PLCβ3 (Imamachi, Park et al. 2009). 
Histamine also activates TRPV1 through PLA2 and LOX causing Ca2+ influxes in  
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sensory neurons (Shim, Tak et al. 2007). Histamine-induced Ca2+ response is attenuated  
by TRPV1 antagonists (Kim, Lee et al. 2004). In TRPV1-/- mice, histamine-induced 
scratching was attenuated suggesting that TRPV1 is a downstream effector of H1R-
mediated itch signaling. Histamine evokes inward currents only when TRPV1 and H1R 
are co-expressed (Shim, Tak et al. 2007).  
 
1.2. TRPV2 
TRPV2 responds to noxious heat (>52ºC) and its expression was observed in 
broader tissues than TRPV1 (Caterina, Rosen et al. 1999; Lewinter, Skinner et al. 2004; 
Lewinter, Scherrer et al. 2008). Although it is unknown whether TRPV2 mediates itch 
signaling pathways, a recent study showed that TRPV2 is expressed in mast cells and 
mediates mast cell degranulation related with pain (Zhang, Spielmann et al. 2011). 
 
1.3. TRPV3 
TRPV3 is activated by innocuous and noxious heat stimuli (>33ºC). TRPV3 is 
expressed in mouse skin but not in DRG (Peier, Reeve et al. 2002). Although TRPV3 is 
co-expressed with TRPV1 in human DRG (Smith, Gunthorpe et al. 2002), major roles of 
TRPV3 in itch have been found in mouse skin. TRPV3 gain-of-function mutant mice 
caused hairless phenotype and spontaneous scratching implicating that TRPV3 may be 
involved in allergic dermatitis development (Yoshioka, Imura et al. 2009). This raises a 
possibility that other TRP channels also can mediate chronic itch. 
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1.4. TRPA1  
TRPA1 is involved in mustard oil-and bradkinin-induced hyperalgesia. TRPA1 
was originally identified as a noxious cold-activated ion channel (>17ºC) (Story, Peier et  
al. 2003). TRPA1 is expressed in a subset of noxious polymodal TRPV1 expressing 
neurons (Dhaka, Viswanath et al. 2006). TRPA1 was recently identified as a downstream 
mediator of MrgprA3 for CQ-induced itch in DRG (Wilson, Gerhold et al. 2011).  
 
1.5. TRPV4 
 Previous siRNA screening identified TRPV4 as a potential itch mediator in 
DRG (Chapter II). TRPV4 was initially characterized as an osmolarity-sensitive channel. 
TRPV4 is involved in warm temperature sensation (>34ºC) and also activated by 4α-
phorbol 12, 13-didecanoate (4αPDD), and epxoxyeicosatrienoic (EET) acids that are 
metabolites of anandamide and arachidonic acid (Eid and Cortright 2009). TRPV4 also 
mediates heat, mechanical and inflammatory pain. TRPV4 mutant mice and antisense 
oligodeoxynucleotide (ODN)-mediated knockdown reduced pain responses (Ding, Wang 
et al.; Alessandri-Haber, Dina et al. 2006; Grant, Cottrell et al. 2007). Although TRPV4 
and TRPV1 share common features for pain, it is not known whether TRPV4 is involved 
in both pain and itch like TRPV1. TRPV4 is expressed in different types of tissues such 
as DRG, skin epidermal keratinocytes and mast cells (Suzuki, Watanabe et al. 2003). 
Therefore, it will be important to find tissue-specific TRPV4 roles in itch pathways. 
Combination of siRNA approaches and mutant mice studies was used to address the 
specific TRPV4 roles for pruritus in DRG. 
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 In this study, TRPV4 was identified as a TRP channel that is necessary for  
transducing both CQ and histamine-elicited acute itch by TRPV4-/- and siRNA treated 
mice. Two different model systems for ACD and dry skin itch were used to examine  
whether TRPV4 mediates chronic itch in mice. Repeated application of chemical hapten, 
2, 4-dinitroflurobenzene (DNFB) induces T cell-mediated hypersensitivity reaction in 
human skin (Garcia-Perez 1978; Perez, Narayan et al. 2004) and accompanying pruritus 
is resistant to anti-histamine treatment (Fig. 34a). Dry skin caused by disrupting 
cutaneous barrier function and characterized with rough, scaly and flaky skin often 
accompanies with chronic pruritus (Yosipovitch 2004). Topical application of 
acetone/ether mixture followed by water (AEW) leads to spontaneous scratching in mice 
resulted from dehydration of skin stratum corneum and epidermal water loss, and dry 
skin itch is also mediated by histamine-independent mechanisms (Akiyama, Carstens et 
al.; Miyamoto, Nojima et al. 2002) (Fig. 34b).  
 TRPV4 expression is uniquely up-regulated in DRG neurons of mice with ACD 
among several TRP channels examined. TRPV4-/- mice with ACD showed significantly 
attenuated pruritus during both the sensitization and elicitation phases without 
compromising the development of classic eczematous skin lesions and inflammatory 
responses. Interestingly, TRPV4-/- mice exhibited normal dry skin-induced pruritus (Fig. 
35). These data suggest that distinct signaling mechanisms underlie ACD- and dry skin-
induced pruritus respectively. Hapten-elicited delayed hypersensitivity may selectively 
involve increased TRPV4 function, while epidermal barrier dysfunction observed in both 
ACD and dry skin condition does not. TRPV4 in DRG neurons may provide a novel  
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therapeutic target for treatment of ACD-induced chronic pruritus. 
 
RESULTS 
 
1. TRPV4 is expression in DRG 
TRPV4 expression was examined in mouse lumbar DRG neurons with different  
markers. TRPV4 is expressed in approximately 19% of total DRG neurons (Fig. 29-32), 
and its expression overlaps with CGRP (61%), IB4 (77%) and NF200 (89%) (Fig. 30 and 
Fig. 31) consistent with the previous report (Suzuki, Watanabe et al. 2003). TRPV4 is 
also co-expressed with 83% of cells expressing GRP, an endogenous ligand for GRPR in 
the spinal cord that is important for histamine-independent itch (Sun and Chen 2007; Sun, 
Zhao et al. 2009). (Fig. 30d-f and Fig. 32a-c). 87% of cells expressing MrgprA3, a 
receptor involved in CQ-evoked itch (Liu, Tang et al. 2009) were TRPV4 positive (Fig. 
32d-f). 70% of cells expressing TRPV1, which is involved in histamine-evoked itch and 
in multiple pruritic pathways through PLCβ3 (Shim, Tak et al. 2007; Imamachi, Park et 
al. 2009) overlap with TRPV4 expressions (Fig. 30 m-o and Fig. 32g-i). TRPV4 is 
completely co-localized with H1R (Fig. 32j-l). This broad expression of TRPV4 in DRG 
suggests that TRPV4 may be involved in multiple itch signaling pathways.  
 
2. TRPV4 is involved in acute itch 
 To examine whether TRPV4 is required for mediating acute pruritoceptive 
transmission, scratching responses of TRPV4-/- mice and WT littermates to i.d. injection  
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of histamine and CQ were observed. In mice, CQ-induced itch is likely to be mediated by 
MrgprA3 and its downstream TRPA1 in DRG neurons (Liu, Tang et al. 2009; Wilson,  
Gerhold et al. 2011), and GRPR in the spinal cord (Sun and Chen 2007). TRPV4-/- mice  
exhibited dramatic reduction of scratching behavior to both histamine and CQ injections 
(Fig. 33a). Apart from DRG neurons, TRPV4 is also expressed in skin and contributes to 
intercellular junction formation in keratinocytes (Sokabe, Fukumi-Tominaga et al. 2010). 
To identify the site of TRPV4 action responsible for histamine and CQ-evoked itch, 
siRNA-mediated knockdown in DRG neurons using i.t. injection was performed taking 
advantage of the fact that TRPV4 is not expressed in the spinal cord (Fig. 29d). Mice 
with TRPV4 deficiency in DRG exhibited marked reduction of scratching behavior 
elicited by both CQ and histamine (Fig. 33b). QRT-PCR confirmed that TRPV4 mRNA 
was significantly reduced in DRG neurons after siRNA injection, whereas TRPV1, 
TRPV2, TRPA1 and TRPM8 expressions were not affected (Fig. 33c). Further, i.t. 
injection of 5, 6-EET, an endogenous TRPV4 agonist (Watanabe, Vriens et al. 2003), was 
used to activate TRPV4 channel in DRG neurons. Activation of TRPV4 in DRG by 5, 6-
EET caused scratching responses in mice. 5, 6-EET-induced scratching behavior was 
significantly reduced in TRPV4-/- mice relative to the control WT mice (Fig. 33e). Taken 
together, these results suggest that activation of TRPV4 in DRG neurons is required for 
mediating both acute histamine and CQ-induced itch.  
 
3. TRPV4 mediates ACD-induced but not dry skin-induced pruritus 
To determine whether TRPV4 has a role in chronic itch, a murine model of ACD  
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was employed. Repeated topical application of DNFB initiates sensitization and  
elicitation phases of ACD in mice (Saint-Mezard, Rosieres et al. 2004; Yamashita, Ito et  
al. 2010). The scratching response appeared at day 3 after the first challenge, reached a 
plateau by day 5. From Day 9 the number of scratching almost doubled compared to the  
previous day, indicating an onset of the second phase. DNFB-induced scratching was 
markedly attenuated in TRPV4-/- mice at day 3 and during the course of 14 day period 
examined (Fig. 33f). This suggests that TRPV4 is required not only for the development 
but also for the maintenance of ACD-induced pruritus. Importantly, among all channels 
and receptors (TRPV1-2, TRPA1, TRPM8, MrgA3, and H1R) examined, TRPV4 is the 
only one whose expression was significantly up-regulated in DRG neurons in mice 
treated with DNFB (Fig. 33d).  
Skin pathology and inflammation were examined in these mice. Despite reduced 
scratching, eczematous skin lesions which are restricted to the painted area around the 
ears (Fig. 36a), thickening of epidermis, infiltration of inflammatory mast cells and 
elevated serum immunoglobulin E (IgE) level were all similar between TRPV4-/- and WT 
mice painted with DNFB (Fig. 36d-f). As expected, LN and spleen (SPL) sizes were all  
significantly increased in DNFB-painted mice suggesting that DNFB painting induces 
inflammatory responses. However, no differences in their size were noted between 
groups (Fig. 36b). In addition, the numbers of neutrophils were increased in both TRPV4-
/- and WT mice with ACD (Fig. 36c). The number of white blood cells (WBC) was also 
increased, but the difference was not statistically significant. Thymic stromal 
lymphopoietin (TSLP), a marker for skin inflammation and dermatitis (Soumelis, Reche  
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et al. 2002; Yoo, Omori et al. 2005; Demehri, Morimoto et al. 2009) also was increased  
about 20 fold after DNFB treatment compared with untreated skin, but TRPV4-/- mice  
also showed similar level of increase (Fig. 36g). Together, these data suggest that after 
initiation, scratching behavior is dependent on TRPV4 but independent of DNFB-induced  
skin inflammation or skin barrier dysfunction. Next, it was examined whether TRPV4 
may have a role in skin dryness (xerosis)-induced itch. However, there was no significant 
difference in scratching behavior between TRPV4-/- mice and their WT littermates after 
AEW treatments (Fig. 35). This is the first evidence that single TRP channel mediates a 
certain type of chronic itch selectively.     
 
4. Functional activation of TRPV4 in DRG is required for itch transmission 
Activation of TRPV4 causes intracellular Ca2+ increase by Ca2+ entry through 
plasma membrane, leading to cell depolarization (Nilius, Vriens et al. 2004). To 
determine whether TRPV4 is directly involved in DRG neuronal activation in response to 
pruritic stimuli, intracellular Ca2+ levels in DRG neurons were examined using 
ratiometric Ca2+ imaging technique. Approximately 14% of DRG neurons showed 
calcium spikes in response to CQ, 21% to histamine and 8% to 5, 6-EET. In contrast, 
TRPV4-/- DRG neurons exhibited significantly decreased percentage of cells that 
responded to CQ (6%), histamine (10%), and 5, 6-EET (1%) (Fig. 37a). In addition, 
TRPV4 siRNA transfection effectively reduced TRPV4 expression in DRG neurons (Fig. 
37c), which also resulted in reduced percentage of responding cells to CQ (6%), 
histamine (15%) and 5, 6-EET (3%), respectively (Fig. 37b). In all experiments, neuronal  
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health was verified with a depolarizing KCl stimulus (Fig. 37d). Single cell RT-PCR  
confirmed that 5, 6-EET responsive cells co-express TRPV4 with GRP and TRPV1 (Fig.  
37e, f). These results further reinforce the idea that TRPV4 activity in DRG neurons is 
directly responsible for mediating pruriceptive transmission.   
 
DISCUSSION 
 
1. TRPV4 in acute itch 
TRPV4 has emerged as the first channel important for both histamine and CQ itch.  
This is unique since previous studies coupled TRPV1 with histamine and TRPA1 with 
CQ itch respectively (Shim, Tak et al. 2007; Wilson, Gerhold et al. 2011). Interestingly, 
both TRPV4 and TRPA1 have similarly been implicated in inflammatory pain (Ceppa, 
Cattaruzza et al. 2010), suggesting that these two channels are likely to be functionally 
related in DRG neurons. Given that MrgprA3 and H1R are necessary for CQ- and 
histamine-induced itch (Han, Mancino et al. 2006; Liu, Tang et al. 2009), future studies 
will be needed to determine whether TRPV4 acts downstream of MrgprA3 or H1R, as 
well as the relationship between TRPV4 and TRPA1 or TRPV1. It will also be interesting 
how it relates with GRPR in the spinal cord. An endogenous TRPV4 agonist, 5, 6-EET, 
which induces scratching responses in vivo can be used to study TRPV4-related itch 
sensory mechanism underlying pruritus. Pacsin3 was identified as a histamine-
independent itch gene from our screening. Pacsin3 can bind to TRPV4 and inhibit its 
function (D'Hoedt, Owsianik et al. 2008). Functional interaction between Pacsin3 and  
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TRPV4 for itch signaling pathways will also provide an interesting insight.  
 
2. TRPV4 in chronic itch 
 The remarkable result arising from this study is that TRPV4 in DRG neurons is 
important for the development of ACD- but not for dry skin-induced pruritus. TRPV4 
expression is uniquely up-regulated in DRG neurons of mice with ACD among several  
TRP channels examined. TRPV4-/- mice with ACD showed significantly attenuated 
pruritus during both the sensitization and elicitation phases without compromising the 
development of classic eczematous skin lesions and inflammatory responses. TRPV4-/- 
mice exhibited normal dry skin-induced pruritus. These data suggest that distinct 
signaling mechanisms underlie ACD- and dry skin-induced pruritus respectively. Hapten-
elicited delayed hypersensitivity may selectively involve increased TRPV4 function, 
while epidermal barrier dysfunction observed in both ACD and dry skin condition does 
not.  
Hapten-induced skin inflammatory response may release endogenous factors to  
activate TRPV4 signaling specifically. Upon encountering with external chemicals, the 
skin cells may release inflammatory mediators that can directly activate TRPV4 
(Alessandri-Haber, Dina et al. 2006), or endogenous 5, 6-EET (Watanabe, Vriens et al. 
2003). Since lack of TRPV4 neither prevents nor abolishes ACD itch, factors other than 5, 
6-EET must be involved. The fact that both ACD and dry skin conditions share epidermal 
barrier dysfunction characterized by an altered stratum corneum, keratinization and water  
content indicates that additional TRPV4-independent signaling may be ascribed to itch  
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associated with the skin barrier dysfunction. 
 In human patients with chronic itch such as atopic dermatitis, scratch-itch- 
inflammation cycles often exacerbate the conditions by damaging the skin and increasing  
the inflammation (Wahlgren 1999). The present study, however, did not indicate a 
correlation between the intensity of scratching behavior and the severity of skin 
inflammation. A recent study also showed that scratching behavior does not necessarily  
correlate with skin inflammations (Kido, Takeuchi et al. 2010). One possibility is that a 
hapten or allergen is capable of initiating specific skin inflammatory response and 
frequent application of DNFB aggravates skin lesions regardless of scratching behavior. 
Alternatively, the remaining scratching bouts in TRPV4-/- mice are sufficient to maintain 
scratching-associated inflammatory components. Insofar as the relationship between 
scratching vs. inflammation associated with human ACD, correlative evidence is still 
lacking.  Moreover, itch-scratch-inflammation cycles may be determined by a 
combination of various factors such as age of animals, type of allergens, and frequency of 
contacts. Hapten-induced immune response appears to follow its signature course as 
indicated by enhanced IgE and TSLP and is dictated by the number of times that skin is 
exposed to environmental substances. Results suggest that activation of TRPV4-
dependent itch signaling in DRG neurons occurs at the sensitization stage, and may be 
maintained and potentiated in the elicitation phase by persistent skin inflammatory 
response. In summary, TRPV4 is a key channel important for mediating both histamine-
dependent and -independent acute itch. Moreover, it is the first TRP channel that has  
been found to be essential for transmitting ACD-induced chronic pruritus. TRPV4 may  
 
54
 
serve as a starting point for designing drugs that help alleviate ACD-induced pruritus. It 
will be important to examine whether i.t. and i.d. applications of TRPV4 specific  
antagonist or siRNA also can inhibit the scratching responses in ACD model because  
they will provide potential therapeutic approaches for ACD-related chronic itch diseases. 
 
MATERIALS AND METHODS 
 
Animals  
C57BL/6J mice were purchased from Jackson laboratory. TRPV4 heterozygous mice 
(Suzuki, Mizuno et al. 2003) (RIKEN BioResource Center, Japan) were bred to generate 
TRPV4-/- mice. Both WT and TRPV4-/- male mice between 7 and 12 weeks were used for 
behavioral experiments. The animal experiments were performed in accordance with the 
guidelines of the National Institutes of Health and were approved by the Animal Studies 
Committee at Washington University School of Medicine. 
 
Double fluorescence ISH and immunohistochemistry (IHC) 
Two different (fluorescein and digoxygenin, Roche)-labeled probes were prepared. 
Fluorescein-labeled probe was purified through G50 microcolumn (Amersham-
Pharmacia) and then precipitated with lithium chloride (LiCl2). Two probes were added 
into hybridization buffer. Procedures were same as the single ISH previously described 
(Birren, Lo et al. 1993). Fluorescent ISH combined with IHC was performed as described 
(Dong, Han et al. 2001). Slides were examined using Olympus BX51 upright microscope  
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attached with a CCD camera. Primary rabbit-GRP (Immunostar, 1:1,000) and TRPV1 
(Neuromics; 1:1,000), guinea pig-CGRP (Peninsula, 1:1,000) and mouse-NF200 (Sigma, 
1:1,000) antibodies were used and followed by incubating with secondary donkey anti-
rabbit or mouse-IgG coupled to FITC (Jackson immunoresearch, 1:400). IB4-FITC 
(Sigma, 1:200) was used to show IB4 stainings.  
 
Acute scratching behavior  
Prior to the experiments, mice were placed in a small plastic chamber (15 × 26 × 12 cm) 
for 30 min to acclimate. Mice were briefly removed from the chamber and intradermally 
injected at the back of the neck with CQ (200μg/50μl saline; Sigma) and histamine 
(500μg/50μl saline; Sigma). 5, 6-EET (Enzo) was diluted into saline and injected 
intrathecally (150pmol/5μl; 0.1% ethanol). Hind limb scratching behavior towards the 
injected area was observed for 30 min with 5 min intervals. One scratch was defined as a 
lifting of the hind limb to the injection site and then a replacing of the limb back to the 
floor, regardless of how many scratching strokes take place between those two 
movements (Sun and Chen 2007). Mouse scratching responses were observed blindly to 
the treatment or genotype of the animals. 
 
In vivo siRNA injection  
TRPV4 mRNA sequence-specific siRNA (Sigma) was dissolved in DEPC-treated PBS. 
ExGen 500 in vivo transfecting reagent (Polyethylenimine (PEI; 0.18μl/1μg siRNA); 
Fermantas) was mixed to enhance siRNA cell penetration. siRNA solution (2.5ug  
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siRNA-PEI mix) was injected into mice intrathecally once daily for three days as 
described (Kawasaki, Xu et al. 2008). After 30 min of the last injection, scratching 
behaviors with pruritogens were monitored for 30 min. DEPC-PBS/PEI mix was used as 
a control. 
 
QRT-PCR  
Lumbar spinal cord dorsal horn and DRG were dissected out from control (DEPC-
PBS/PEI) and siRNA-treated mice, and were homozenized with Dounce glass 
homogenizer (Wheaton) and total RNA was prepared by using Trizol reagent 
(Invitrogen). cDNA was synthesized using Superscript First-strand synthesis system 
(Invitrogen) and conventional or QRT-PCR was performed using iQ SYBR Green  
Supermix (Bio-Rad) and Mx3000P qPCR system (Stratagene). Expression of target 
mRNA was normalized to 18S ribosomal RNA (rRNA) level. The followings are primers 
used for PCR.  
18sRNA,  5’-AAACGGCTACCACATCCAAG-3’ and   
                 5’-CCTCCAATGGATCCTCGTTA-3’ 
TRPV1,   5’-GTGATCGCCTACAGTAGCAGTG-3’ and  
                5’-ACATGTGGAATACAGGCTGTTG-3’ 
TRPV2,   5’-GGTGGTTTTAGAGCCACTGAAC-3’ and  
                5’-GTAGATGCCTGTGTGCTGAAAG-3’ 
TRPV4,   5’-GAGAACACCAAGTTTGTCACCA-3’ and  
                5’-TGAATCATGATGCTGTAGGTCC-3’ 
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TRPA1,   5’-AGTATCATCTTCGTGTTGCCCT-3’ and  
                5’-AGTCTCCCACTCCCATAAGACA-3’ 
TRPM8,  5’-ATGAATATGAGACCCGAGCAGT-3’ and  
                5’-GCAAAGAGGAACAGGAAGAAGA-3’ 
MrgA3,   5’-GGCATCACCTGGTTCCTGTTA-3’ and  
                5’-CCAGTGAGGCATGTCAAGTCA-3’ 
H1R,       5’-AGAGCATCTGAAAGAGACCCAG-3’ and  
               5’-GTTCTCATCCCAAGTTTCCAAG-3’ 
TSLP,     5’- CCAGGCTACCCTGAAACTGA-3’ and  
               5’- TCTGGAGATTGCATGAAGGA-3’ 
 
Allergic contact dermatitis (ACD) model  
2, 4-Dinitrofluorobenzene (DNFB; Sigma) was dissolved in acetone. 50 μl of 0.15% 
DNFB acetone solution was applied on the back skin of neck every other day (Saint-
Mezard, Rosieres et al. 2004; Yamashita, Ito et al. 2010). This was repeated for two 
weeks and scratch responses were measured every morning (24hrs after painting) for 30 
min with 5 min intervals. 
 
Dry skin model  
Cotton soaked with acetone/diethylether (AE; 1:1) was put on the  
shaved area of neck for 15 sec and then distilled water was applied for 30 sec. This 
treatments were performed twice a day and repeated once daily for five days (Miyamoto,  
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Nojima et al. 2002). The number of scratch was counted after 5 min of water treatment 
for 30 min with 5 min intervals.  
 
Skin histology 
For hematoxylin and eosin (H&E) and toluidine blue staining using paraffin-embedded 
tissue sections, skin was fixed in 4% paraformaldehyde in PBS, dehydrated with ethanol 
and embedded in paraffin. It was sectioned at 5μm. 
 
ELISA 
Serum IgE was measured using Mouse IgE ELISA kit (Immunology Consultants 
Laboratory Inc., Newberg, OR) 
 
White Blood Cell Count  
Blood samples collected from the mandibular vein were used for hematological analysis 
with Hemavet 950 analyzer (Drew Scientific Inc., Oxford, CT), which included white 
blood cells (WBC) and differential counts. 
 
DRG culture, siRNA transfection and Ca2+ imaging 
DRG were dissected in neurobasal media (Invitrogen) and incubated with papain 
(30μl/2ml neurobasal; Worthington) at 37ºC for 20 min. After washing with PBS, cells 
were incubated with collagenase (3mg/2ml neurobasal; Worthington) at 37ºC for 20 min. 
After washing with PBS, cells were dissociated with flame polished glass pipette in  
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neurobasal media. Dissociated cells were collected through cell strainer (BD Biosciences) 
to remove tissue debris. Dissociated DRG cells were re-suspended with DRG culture 
media (2% Fetal bovine seum, 2% Horse serum, 2% B-27 supplement and 1x Glutamine 
in neurobasal media; Invitrogen) and plated onto poly-ornithine-coated 12 mm diameter 
round glass coverslips in 24-well plate. siRNA stock solution was prepared as described 
previously (in Chapter II). DRG cells were transfected with siRNA (60 pmol) by using 
Lipofectamine 2000 reagent (Invitrogen). After 24 hours, cell culture media was replaced 
with Ca2+ imaging buffer and cells were loaded with Fura-2 (2μM) diluted in the Ca2+ 
imaging buffer. Ca2+ imaging was performed as shown in the previous section (Chapter 
II). CQ (1mM), histamine (100μM) and 5, 6-EET (300pM) were applied to DRG cultures 
to examine Ca2+ responses.  
 
Single-cell RT-PCR  
Single-cell RT-PCR was performed as previously described (Park, Kim et al. 2006). 
DRG neurons were aspirated into a glass patch pipette with a tip diameter of 25-30μm by 
applying negative pressure using CellTram Vario (Eppendorf). Cells were gently put into 
a reaction tube containing reverse transcription reagents and incubated for 1 hr at 50°C 
(Superscript III, Invitrogen). The first round of PCR was preformed in 50 μl of PCR 
buffer containing 0.2 mM dNTPs, 0.2 μM outer primers, 5 μl cDNA and 0.2 μl platinum 
Taq DNA polymerase (Invitrogen). The reactions were denatured initially for 5 min at 
95 °C followed by 40 cycles of 40 sec denaturation at 95 °C, 40 sec annealing at 55 °C, 
and 40 sec elongation at 72 °C. The reaction was completed with 7 min of final  
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elongation. For the second round of amplification, the reaction buffer (20 μl) contained 
0.2 mM dNTPs, 0.2 μM inner primers, 5 μl of the first round PCR products and 0.1 μl 
platinum Taq DNA polymerase (Invitrogen). The reaction procedure was the same as the 
first round. A negative control was obtained from pipettes that did not harvest any cell 
contents, but were submerged in the bath solution. PCR products were displayed on 
ethidium bromide-stained 1% agarose gels.  
PCR primers are as follows:  
Actin (outer),      5’-TGTTACCAACTGGGACGACA-3’ and 
                            5’-TCTCAGCTGTGGTGGTGAAG-3’  
Actin (inner)       5’-GATCTGGCACCACACCTTCT-3’ and  
                            5’-ACGCTCGGTCAGGATCTTC-3’  
TRPV1 (outer)    5’-TGATCATCTTCACCACGGCTG-3’ and  
                            5’-CCTTGCGATGGCTGAAGTACA-3’;  
TRPV1 (inner)    5’-AAGGCTTGCCCCCCTATAA-3’ and  
                            5’-CACCAGCATGAACAGTGACTGT-3’ 
GRP (outer)         5’-CCAAGGAGCAAAACAAAACCC-3’ and  
                             5’-GCAAATTGGAGCCCTGAATCT-3’ 
GRP (inner)         5’-AGACTGCCTTCTGCAAACGTC-3’ and  
                             5’-AAGCCTAGCTGGAAAAAGCG-3’ 
 
Statistical analysis  
Statistical analysis was performed with Student’s t-test or two-way repeated measured  
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analysis of variance (ANOVA). All data were expressed as the mean ± standard error 
mean (SEM) and error bars represent SEM in all cases, p< 0.05 was  
considered statistically significant. 
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V. CONCLUSIONS AND FUTURE DIRECTIONS 
 
Although itch was defined as an unpleasant sensation that elicits the desire to 
scratch by German physician Samuel Hafenreffer in 1660 (Rothman 1941), itch has been 
put aside because it was thought as a minor form of somatosensation relative to pain. Itch 
and pain are closely related each other. Mild mechanical stimulation (or pain) by 
scratching can inhibit itch. Nociceptive stimuli like noxious heat reduce itch while itch 
can be induced by antagonizing pain via opioids (Szarvas, Harmon et al. 2003). Both itch 
and pain can be elicited by multiple mechanical and chemical stimuli through similar 
neuronal populations. Although several studies found critical components for itch 
pathways, the identity of neural circuit transmitting itch and basic molecular mechanism 
have yet to be clearly defined. While the relation between itch and pain is still unclear, 
itch researchers have recently provided evidences suggesting that itch is a distinct 
sensation from pain. Currently, itch is being recognized as a medical problem, especially 
in chronic itch diseases such as AD. It is impossible to establish an efficient therapeutic 
method without understanding molecular mechanism of itch signaling pathways in the 
nervous system.  
 First, we identified novel itch-related molecules in the spinal cord and DRG by 
differential screening. LCM was used to dissect superficial dorsal horn including lamina I 
and II. This made the screening feasible with a tiny region of the spinal cord where 
GRPR is expressed. Another important experimental approach used in this study is in 
vivo siRNA-mediated gene knockdown in the spinal cord and DRG. i.t. injection of  
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siRNA affects spinal cord and DRG gene expression, therefore, siRNA provides tissue  
selectivity like conditional KO. One of the advantages of in vivo siRNA is that siRNA 
effect can be verified by behavioral test directly. In vitro siRNA transfection using cell 
culture may support certain gene functions in itch signaling but this will raise a question 
whether in vitro system is same as in vivo status. In vivo siRNA circumvents this 
potential problem of in vitro approaches. The primary purpose of the screening was to 
identify additional novel itch receptors and GRPR downstream signaling molecules, 
Atp2a1 and Itpr3 were found indicating that intracellular Ca2+ signaling is important for 
itch sensation. Identification of GRPR expressing neurons as itch specific cells (Sun, 
Zhao et al. 2009) supports the idea that there are neuronal populations for itch-dedicated 
pathways in the spinal cord. Functional studies of Atp2a1 and Itpr3 involved in GRPR-
mediated histamine-independent pathways suggests that there are different types of 
signaling for distinct itch sensations in single cell. Although similar molecules can be 
involved in multiple pathways, isoform-specific mediators still can distinguish two 
different itch signaling pathways. Differential screening was performed with the spinal 
cord treated with bombesin-saporin but GRPR is also expressed in DRG (Fig. 22 and 23). 
Previous study confirmed that bombesin-saporin did not change DRG primary afferent 
markers innervated in the spinal cord (Sun, Zhao et al. 2009). However, this still does not 
exclude the possibility that bombesin-saporin may affect GRPR expressing cells in DRG. 
The DRG may provide additional place where potentially interesting itch receptors are 
located. It will be worth while to study DRG gene expressions after bombesin-saporin 
treatment. Receptors and downstream mediators are critical components of signaling  
 
64
 
pathways but these can be regulated by gene expression level changes. It is unclear how 
expressions of itch-related genes are regulated. To identify molecular mechanism of itch 
pathways controlled by transcriptional changes, candidate genes encoding transcription 
factors can be further studied. If certain itch genes like GRPR are expressed under control 
of specific transcription factors, this will provide a missing link between itch signaling 
pathways and gene expressions.  
 Second, previous studies with GRPR (Sun and Chen 2007) only focused on the 
spinal cord. In this study, we found peripheral GRPR roles in itch. However, there are 
still several questions to be addressed. Compared with i.t. injection (1 nmol), GRP i.d. 
injection requires much higher dose (100 nmoles) (Fig. 24a). GRP may be easily 
degraded in the skin or can not diffuse well. It is uncertain whether GRP activates GRPR+ 
free nerves, epidermal keratinocytes or mast cells. Because we don’t know the exact 
mechanism of peripheral GRP-GRPR activation for itch, it will be necessary to study 
peripheral GRPR roles using tissue-specific conditional KO mice. Peripheral GRPR is 
also important in chronic itch (Fig. 28). DCP-painted mice model was used to represent 
human contact dermatitis. In addition to acute itch induced by CQ and histamine, it is 
important to understand chronic itch pathways to establish an efficient therapeutic 
method. This will translate basic molecular mechanism of itch to clinical relevance in 
human.  
 Third, TRPV4 was identified from siRNA screening. One of the candidate genes 
from differential screening with bombesin-saporin treated spinal cord was Pacsin3. 
Although TRPV4 is not expressed in the spinal cord, Pacsin3 was known to bind TRPV4  
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and regulates TRPV4 activity (D'Hoedt, Owsianik et al. 2008). Because Pacsin3 and  
TRPV4 are expressed in DRG, it is possible that both can be involved in itch sensory  
pathways. Functional studies of TRPV4 by siRNA and KO mice confirmed that TRPV4  
is an important TRP channel in DRG for both acute and chronic itch. It is interesting that 
TRPV4 mediates both histamine-dependent and -independent itch in that the other TRP 
channels such as TRPV1 and TRPA1 are involved in either type of itch. i.t. injection of 
an endogenous TRPV4 agonist, 5, 6-EET caused scratching behaviors in mice (Fig. 33e). 
5, 6-EET also induced intracellular Ca2+ increase in DRG neurons (Fig. 37d, e). 
Although Ca2+ response is one indicator of cellular activities, it does not always represent 
neuronal activation such as action potential firings. Therefore, electrophysiological 
studies with TRPV4 agonist and antagonist in normal and chronic itch mice DRG will be 
required to verify neuronal TRPV4 functions for itch. Another important finding is that 
an increased TRPV4 expression in DRG is responsible for aggravated itch/scratching 
responses in ACD mice model (Fig. 33d). This broad involvement of TRPV4 in itch 
makes it more interesting itch therapeutic target. To examine relationships between 
TRPV4 and other TRP channels such as TRPA1 and TRPV1, siRNA and KO mice 
studies can be combined. GRP and GRPR are critical itch mediators in DRG and spinal 
cord. It will be also an interesting question how TRPV4 is related with GRP and GRPR-
mediated pathways. These studies will help understand itch signaling pathways in 
peripheral DRG neurons in detail. 
Itch is well conserved in vertebrates. It has long been considered as a basic 
sensory or defensive mechanism to protect our body from external harmful reagents.  
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However, it is now being recognized as a medical problem in clinical field. Itch is closely  
related with our daily life. Bug (mosquito) bite, contact allergen such as pollens, plants 
(poison ivy), chemicals and metals (nickel) cause human itching. Climate condition like  
dryness affect skin status and induce itchness. Patients with chronic itch disease such as 
AD and psoriasis, immune system defects, and systemic liver disease are suffering from 
intractable itch symptoms. Several therapeutic approaches such as dialysis for renal 
failure, cancer therapy and pain drugs have itch as side effects and this reduces their 
effectiveness. Recent studies have identified critical components of itch signaling 
pathways but our knowledge about detail mechanism of pruritus is still infancy. The 
results in this thesis work will further advance our knowledge about itch sensory 
mechanism and provide therapeutic insights for itch-related human diseases. 
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Figure 1. Neuronal circuits for somatosensations.  
(a) Skin receives external sensory inputs through peripheral nerves. Sensory information is  
relayed through DRG and spinal cord. DRG has distinct cell populations that express specific  
receptors recognizing various stimuli. Spinal cord dorsal horn has multiple laminar layers.  
Superficial dorsal horn is an important place to transmit the somatosensory signals to brain  
producing proper responses to external environment. Therefore, it will be interesting to identify  
Itch-specific molecules in these neuronal circuits. Modified from (Patapoutian, Peier et al. 2003).  
(b) Spinal cord dorsal horn lamina I and II are shown by SP (red) and IB4 (green) immunostaining.  
(c) Different populations of DRG neurons expressing TRPV4 (red), GRP (green) and both 
(yellow). (d) CGRP+ free nerve endings are innervated into skin epidermis as shown by CGRP  
immunostaining (Red). SP : Substance P, IB4 : Isolectin B4, CGRP : Calcitonin gene-related  
peptide 
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(a) Bom slation. 1. Bombesin-saporin binds 
to GRPR, 2. Bombesin-saporin bound GRPR is internalized into cytosol by endocytosis. 3. 
Saporin is released by proteolysis. 4. Saporin inhibits protein translation by targeting ribosomal  
RNAs. 5. Failure of protein synthesis causes cell death. BOM : Bombesin. Modified from  
(Wiley 2000) (b, c) In situ hybridization shows that GRPR expressing cells were ablated by  
bombesin-saporin treatment. (d) QRT-PCR confirmed that bombesin-saporin treatment 
selectively reduced GRPR expression without affecting other superficial dorsal horn marker 
genes (Student t-test, p<0.05, n=9). NK1R : Tachykinin receptor 1 , NMBR : Neuromedin B 
receptor, NMUR2 : Neuromedin U receptor 2, BRS3 : Bombesin-like receptor 3 
                                                                                                
                                                                                                
Figure 2. GRPR cell ablation by bombesin-saporin. 
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Figure 3. Differential screening to identify itch genes in GRPR neurons.  
1. Blank- and bombesin-saporin treated spinal cord dorsal horn superficial layers were dissected 
using laser capture microscope (LCM). 2. Total RNA was extracted and amplified. RNA integrity 
was measured by Bio-analyzer. 3. cDNA was synthesized and hybridized with illumine bead array. 
4. Microarray data were analyzed with Partek Genome Suite and Ingenuity Pathway Analysis 
(IPA). 5. Candidate genes were verified by QRT-PCR, in situ hybridization (ISH) and behavioral 
tests. 6. siRNA studies further confirmed the roles of candidate genes in itch sensation.  
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Table 1. Microarray candidate genes that have reduced expressions in bombesin-saporin  
treated spinal cord.  
SYMBOL Gene 
Fold 
Change Frequency
 Grpr  Gastrin releasing peptide receptor  - 6 9 
 Glp2r  Glucagon-like peptide 2 receptor  - 5 9 
 V1rf1  Vomeronasal 1 receptor, F1  - 4 9 
 Fgfr3  Fibroblast growth factor receptor 3  - 4 9 
 Kcne1  Potassium voltage-gated channel, Isk-related subfamily, member 1  - 4 9 
 Taar7e  Trace amine-associated receptor 7E  - 4 9 
 Fpr-rs6  Formyl peptide receptor, related sequence 6  - 3 9 
 Tnfrsf7  Tumor necrosis factor receptor superfamily, member 7 - 3 9 
 Tas2r119  Taste receptor, type 2, member 119  - 3 9 
 Xlkd1  Lymphatic vessel endothelial hyaluronan receptor  - 3 9 
 Grm1  Glutamate receptor, metabotropic 1  - 3 9 
 Ptger4  Prostaglandin E receptor 4 - 2 9 
 Tlr5  Toll-like receptor 5 - 6 8 
 Cd244  CD244 natural killer cell receptor 2B4  - 5 8 
 Kcnj15  Potassium inwardly-rectifying channel, subfamily J, member 15  - 4 8 
 Kcng1  Potassium voltage-gated channel, subfamily G, member 1 - 3 8 
 V2r15  Vomeronasal 2, receptor 30 - 3 8 
 Il27ra  Interleukin 27 receptor, alpha  - 3 8 
 Kcnq2  Potassium voltage-gated channel, subfamily Q, member 2  - 3 8 
 Klra9  Killer cell lectin-like receptor subfamily A, member 9  - 3 8 
 C5r1  Complement component 5a receptor 1 - 2 8 
 Gabt4  Solute carrier family 6 (neurotransmitter transporter, GABA),    member 11  - 2 8 
 Gpr18  G protein-coupled receptor 18  - 11 7 
 Gpr133  G protein-coupled receptor 133  - 7 7 
 Esrrb  Estrogen related receptor, beta  - 5 7 
 Gpr35  G protein-coupled receptor 35  - 4 7 
 GPR106  LGR8, GPCR, relaxin/insulin-like family peptide receptor 2 - 3 7 
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 Gpr31c  G protein-coupled receptor 31, D17Leh66c region  - 3 7 
 Npy5r  Neuropeptide Y receptor Y5  - 2 7 
Atp2a1  ATPase, Ca++ transporting, cardiac muscle, fast twitch 1  - 10 6 
 Mrgprb4  MAS-related GPR, member B4  - 10 6 
 Ret  ret proto-oncogene  - 9 6 
 Gpr73  Prokineticin receptor 1 (Prokr1, PKR1) - 7 6 
 Mrgpra3  MAS-related GPR, member A3  - 6 6 
 P2rx4  Purinergic receptor P2X, ligand-gated ion channel 4 - 5 6 
 Mrgpra2  MAS-related GPR, member A2  - 5 6 
 Accn3  Amiloride-sensitive cation channel 3  - 4 6 
 Sorcs1  VPS10 domain receptor protein SORCS 1  - 4 6 
 Edg7 
 Endothelial differentiation, lysophosphatidic acid G-protein-coupled    
 receptor 7  - 3 6 
 Mrgpra7  MAS-related GPR, member A7  - 3 6 
 Chrm2  Cholinergic receptor, muscarinic 2, cardiac  - 3 6 
 Cacna1b  Calcium channel, voltage-dependent, N type, alpha 1B subunit - 3 6 
 Cacna1c  Calcium channel, voltage-dependent, L type, alpha 1C subunit  - 3 6 
 Il1r2  Interleukin 1 receptor, type II  - 2 6 
 Lbr  Lamin B receptor  - 2 6 
 Itpr3  Inositol 1,4,5-triphosphate receptor 3 - 2 6 
 Anktm1  Transient receptor potential cation channel, subfamily A, member 1  - 2 6 
 Scn4b  Sodium channel, type IV, beta  - 2 6 
 Sstr4  Somatostatin receptor 4  - 2 6 
 Trpc6  Transient receptor potential cation channel, subfamily C, member 6  - 2 6 
 Paqr3  Progestin and adipoQ receptor family member III  - 2 6 
 Htr1b  5-hydroxytryptamine (serotonin) receptor 1B  - 4 5 
 Ptgdr  Prostaglandin D receptor  - 2 5 
 Il17rb  Interleukin 17 receptor B  - 2 5 
 
 
 
 
 Nr3c2  Nuclear receptor subfamily 3, group C, member 2 - 7 4 
 Tlr6  Toll-like receptor 6  - 5 4 
 V1rl1  Vomeronasal 1 receptor, L1  - 4 4 
 V1rh10  Vomeronasal 1 receptor, H10  - 3 4 
 Fgfr4  Fibroblast growth factor receptor 4 - 2 4 
 Tas2r105  Taste receptor, type 2, member 105  - 10 3 
 Sstr2  Somatostatin receptor 2  - 10 3 
 Cacnb1  Calcium channel, voltage-dependent, beta 1 subunit  - 9 3 
 Oprd1  Opioid receptor, delta 1 (DOR) - 9 3 
 Celsr2  Cadherin, EGF LAG seven-pass G-type receptor 2 - 8 3 
 Oprm1  Opioid receptor, mu 1 (MOR) - 8 3 
 Trik  Potassium channel, subfamily K, member 18  - 6 3 
 5-Htr2c  5-hydroxytryptamine (serotonin) receptor 2C  - 6 3 
 Pparg  Peroxisome proliferator activated receptor gamma  - 6 3 
 Mrc2  Mannose receptor, C type 2 - 5 3 
 Clic6  Chloride intracellular channel 6  - 5 2 
 P2ry10  Purinergic receptor P2Y, G-protein coupled 10  - 5 3 
 Il18r1  Interleukin 18 receptor 1 - 4 3 
 Tas2r136  Taste receptor, type 2, member 136  - 4 3 
 Scnn1b  Sodium channel, nonvoltage-gated 1 beta  - 4 3 
 Mrgprx1  MAS-related GPR, member X1  - 4 3 
 Adora3  Adenosine A3 receptor  - 4 3 
 Htr7  5-hydroxytryptamine (serotonin) receptor 7 - 4 3 
 Ppyr1  Pancreatic polypeptide receptor 1  - 4 3 
 V1ri9  Vomeronasal 1 receptor, I9  - 3 3 
 Gfra3  Glial cell line derived neurotrophic factor family receptor alpha 3  - 3 3 
 Trpm1  Transient receptor potential cation channel, subfamily M, member 1  - 3 3 
 Mc2r  Melanocortin 2 receptor  - 3 3 
 Klra12  Killer cell lectin-like receptor subfamily A, member 12  - 3 3 
 V1rh1  Vomeronasal 1 receptor, H1  - 3 3 
 V2r15  Vomeronasal 2, receptor 30 - 3 3 
 Igf1r  Insulin-like growth factor I receptor  - 3 3 
 P2ry2  Purinergic receptor P2Y, G-protein coupled 2  - 3 3 
 Catsper3  Cation channel, sperm associated 3  - 3 3 
 V1rd13  Vomeronasal 1 receptor, D13 - 3 3 
 Il7r  Interleukin 7 receptor  - 3 3 
 V1rc33  Vomeronasal 1 receptor, C33  - 3 3 
 Nptxr  Neuronal pentraxin receptor - 2 3 
 Npr1  Natriuretic peptide receptor 1 - 2 3 
 Kcna10  Potassium voltage-gated channel, shaker-related subfamily,  member 10  - 2 3 
 Kcnc3  Potassium voltage gated channel, Shaw-related subfamily, member 3  - 2 3 
 Tas2r110  Taste receptor, type 2, member 110 - 2 3 
 V1rc23  Vomeronasal 1 receptor, C23  - 2 3 
 Avpr1b  Arginine vasopressin receptor 1B  - 2 3 
 Kcnf1  Potassium voltage-gated channel, subfamily F, member 1  - 2 3 
 V1rc21  Vomeronasal 1 receptor, C21  - 2 3 
 Ildr1  Immunoglobulin-like domain containing receptor 1  - 2 3 
 Klri1  Killer cell lectin-like receptor family I member 1  - 2 3 
 Mc3r  Melanocortin 3 receptor  - 2 3 
 Chrng  Cholinergic receptor, nicotinic, gamma polypeptide  - 12 2 
 Tas2r126  Taste receptor, type 2, member 126  - 6 2 
 Kcnk4  Potassium channel, subfamily K, member 4  - 5 2 
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 Esrrg  Estrogen-related receptor gamma  - 5 2 
 V1rh9  Vomeronasal 1 receptor, H9  - 5 2 
 Calcr  Calcitonin receptor, transcript variant a - 5 2 
 V2r10  Vomeronasal 2, receptor 89 - 5 2 
 Gabrp  Gamma-aminobutyric acid (GABA-A) receptor, pi  - 4 2 
 Folr4  Folate receptor 4 (delta) (Folr4), transcript variant 2 - 3 2 
 Kcnk4  Potassium channel, subfamily K, member 4 - 3 2 
 V2r1b  Vomeronasal 2, receptor 26 - 3 2 
 Ptger2  Prostaglandin E receptor 2 (subtype EP2)  - 3 2 
 Cntfr  Ciliary neurotrophic factor receptor  - 3 2 
 Mass1  G protein-coupled receptor 98  - 2 2 
 Tlr9  Toll-like receptor 9  - 2 2 
 Cnga2  Cyclic nucleotide gated channel alpha 2  - 2 2 
 Ncr1  Natural cytotoxicity triggering receptor 1  - 2 2 
 Gpr43  Free fatty acid receptor 2 (Ffar2) - 2 2 
 Tnfrsf22  Tumor necrosis factor receptor superfamily, member 22  - 2 2 
 Mrgpra8  MAS-related GPR, member A8 - 2 2 
 
Candidate genes were selected if their fold change (negative) and frequency are higher than 2. 
123 genes encoding receptor, channel and membrane protein were considered as primary 
targets. Gray: not reduced in QRT-PCR, Yellow: reduced in QRT-PCR,  
Blue: not confirmed by agonists or antagonists, Red: confirmed by agonists or antagonists  
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Figure 4. QRT-PCR showed that 16 genes have reduced expression levels in  
bombesin-saporin treated samples. QRT-PCR was performed with total RNA from superficial 
layers of dorsal spinal cord dissected by LCM. 18sRNA was used as a reference to calculate 
relative fold change between control (blank-saporin) and bombesin-saporin treated samples.  
Student t-test (p<0.05, N=9)  
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Figure 5. ISH showed that 8 candidate genes are expressed in the spinal cord dorsal horn.  
ISH was performed for 16 genes confirmed by QRT-PCR. Half of them showed specific ISH  
signals in the spinal cord.  
 
 
   
 
        
Figure 6. ISH showed that expressions of 4 candidate genes were decreased in the  
bombesin-saporin treated spinal cord. Cervical spinal cord from blank- and bombesin-saporin  
treated spinal cord was used for ISH to compare candidate gene expressions between them.  
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Figure 7. Atp2a1 inhibitor, DBHQ and TG, i.t. injections inhibited histamine-independent  
itch. DBHQ (10μg, vehicle: 5%DMSO) and TG (5μg, vehicle: saline) were injected intrathecally  
10 min before GRP (0.5nmol, i.t.), CQ (200μg, i.d.) and histamine (1mg, i.d.) treatments.  
Student t-test (*p<0.05, **p<0.01, ***p<0.001) was used for statistical analysis (n=8).  
DBHQ: 2, 5-Di-tert-butylhydroquinone, TG: Thapsigargin, CQ: Chloroquine,  
i.t.: intrathecal injection, i.d.: intradermal injection 
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Table 2. Microarray candidate genes that may be involved in Ca2+ signaling.  
SYMBOL Gene 
Fold 
Change Frequency 
 Atp2a1  ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 - 6 10 
 Pip5k1c  Phosphatidylinositol-4-phosphate 5-kinase - 6 9 
 Grpr  Gastrin-releasing peptide receptor  - 6 9 
 Rgr3  Regulator of G-protein signaling 13 - 2 9 
 Pla2g1b  Phospholipase A2, group IB, pancreas - 17 8 
 Pik3c2g 
 Phosphatidylinositol 3-kinase, C2 domain containing,   
 gamma polypeptide - 5 8 
 Arhgap19  Rho GTPase activating protein 19 - 4 8 
 Pld3  Phospholipase D family, member 3 - 3 8 
 Pacsin3  Protein kinase C and casein kinase substrate in neurons 3 - 3 8 
 Gps1  G protein pathway suppressor 1 - 2 8 
 Itpkb  Inositol 1,4,5-trisphosphate 3-kinase B - 4 7 
 Arfgap1  ADP-ribosylation factor GTPase activating protein 1 - 3 7 
 Rohn  Rho family GTPase 2 - 3 7 
 Cabp4  Calcium binding protein 4 - 4 6 
 Pde6d  Phosphodiesterase 6D, cGMP-specific, rod, delta - 4 6 
 Pla2g5  Phospholipase A2, group V - 3 6 
 Pitpnc1  Phosphatidylinositol transfer protein, cytoplasmic 1 - 2 6 
 Prkcm  Protein kinase C, mu - 2 6 
 Rgs4  Regulator of G-protein signaling 4 - 2 6 
 Rgs11  Regulator of G-protein signaling 11 - 2 4 
 S100a8  S100 calcium binding protein A8 (calgranulin A) - 4 3 
 Racgap1  Rac GTPase-activating protein 1 - 4 3 
 Gnat3  Guanine nucleotide binding protein, alpha transducing 3 - 2 3 
 Rdgb2 
 Phosphatidylinositol transfer protein, membrane- 
 associated 2 - 2 3 
 Pde6g  Phosphodiesterase 6G, cGMP-specific, rod, gamma - 2 3 
 Pla2g3  Phospholipase A2, group III - 2 3 
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 Pla2g4d  Phospholipase A2, group IVD - 10 2 
 Pik3r2 
 Phosphatidylinositol 3-kinase, regulatory subunit,   
 polypeptide 2 (p85 beta) - 3 2 
 Arhgap8  Rho GTPase activating protein 8 - 3 2 
 Plcz1  Phospholipase C, zeta 1 - 2 2 
 Rgs3  Regulator of G-protein signaling 3 - 2 2 
 
30 candidate genes were selected for potential GRPR downstream Ca2+ signaling molecules 
 
Table 3. QRT-PCR further selected 11 Ca2+ signaling candidate genes that showed  
reduced expressions in bombesin-saporin treated spinal cord.  
SYMBOL Gene 
Fold 
Change Frequency 
 Atp2a1  ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 - 6 10 
 Pip5k1c  Phosphatidylinositol-4-phosphate 5-kinase - 6 9 
 Pik3c2g 
 Phosphatidylinositol 3-kinase, C2 domain containing,   
 gamma polypeptide - 5 8 
 Pld3  Phospholipase D family, member 3 - 3 8 
 Pacsin3  Protein kinase C and casein kinase substrate in neurons 3 - 3 8 
 Itpkb  Inositol 1,4,5-trisphosphate 3-kinase B - 4 7 
 Prkcm  Protein kinase C, mu - 2 6 
 Itpr3  Inositol 1,4,5-triphosphate receptor 3 - 2 6 
 S100a8  S100 calcium binding protein A8 (calgranulin A) - 4 3 
 Pik3r2 
 Phosphatidylinositol 3-kinase, regulatory subunit,    
 polypeptide 2 (p85 beta) - 3 2 
 Plcz1  Phospholipase C, zeta 1 - 2 2 
 Itpr3  Inositol 1,4,5-triphosphate receptor 3 - 2 6 
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Table 4. 11 ER-Ca2+ related genes for siRNA screening.  
 PLB  Phospholamban 
 SLN  Sarcolipin 
 Calnexin  Calnexin 
 CALR  Calreticulin 
 Erp57  ER oxidoreductase  
 DSP  Desmoplakin 
 Pik3r2  Phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) 
 Arhgap8  Rho GTPase activating protein 8 
 Plcz1  Phospholipase C, zeta 1 
 Rgs3  Regulator of G-protein signaling 3 
 TRPV4 Transient receptor potential (TRP) vanilloid 4 ion channel  
 
Target genes were decided by QRT-PCR results and functional relations with ER-Ca2+  
signaling pathways.  
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Figure 8. Atp2a1 siRNA i.t. injection decreased CQ-induced scratching.  
(a) Atp2a1 siRNA treated mice showed reduced CQ-induced scratches but not histamine-itch. (b) 
Another isoform of Atp2a gene, Atp2a2 siRNA did not change both CQ and histamine-induced 
scratches suggesting that the Atp2a1 siRNA effect is specific to Atp2a1. siRNA effect was 
confirmed by QRT-PCR and ISH. (c) QRT-PCR showed that Atp2a1 siRNA decreased spinal 
cord Atp2a1 expressions more significantly than DRG. (d) ISH confirmed that Atp2a1 expressions 
were reduced in the spinal cord dorsal horn.  
Control: PEI/DEPC-PBS, Student t-test (*p<0.05, **p<0.01, ***<0.001, n=9)  
PEI : Polyethylenimine, DEPC : Diethylprocarbonate, PBS : phosphate-buffered saline 
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Figure 9. Atp2a gene has three different isoforms. (a) QRT-PCR showed that Atp2a1  
expression level was significantly decreased in bombesin-saporin treated spinal cord but  
Atp2a2 expression was not affected (n=9). (b-c) Atp2a1 and Atp2a2 are expressed in the  
spinal cord. While Atp2a1 was strongly expressed in the superficial dorsal horn, Atp2a2  
expression was examined in deep dorsal horn and ventral horn. (d) Atp2a3 was not detected  
in the spinal cord. (e-f) Bombesin-saporin treatment decreased Atp2a1 expressions in the  
superficial dorsal horn without affecting Atp2a2. (g) Atp2a3 probe detected Atp2a3  
expressions in the cerebellum granular cell layers. (h-j) ISH showed that Atp2a1 and Atp2a2  
are also expressed in DRG. Atp2a3 is not expressed in DRG. Scale bars, 100μm (b-f); 50μm (h-j) 
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Figure 10. Atp2a1 is co-localized with GRPR in the spinal cord and DRG.  
(a-c) spinal cord GRPR neurons co-express Atp2a1. (d-f) Most GRPR expressing neurons  
in DRG are co-localized with Atp2a1(88%, 84/96). (g-i) Specificity of GRPR staining in DRG  
was confirmed with GRPR mutant DRG.  
(a-c) Atp2a1 fluorescent ISH (FISH)-GRPR immunostaining,  
(d-i) Atp2a1-GRPR double FISH, Scale bar, 50μm  
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(Continued) 
 
                    
                    
Figure 11. Expression and characterization of Atp2a1 cells in the spinal cord and DRG.  
Atp2a1 is broadly expressed in the spinal cord dorsal horn (a-c, g-i). Atp2a1 is co-expressed  
with CGRP (d-f, 30%, 37/122), IB4 (j-l, 29%, 90/306), NF200 (m-o, 26%, 51/195),  
MrgprA3 (p-r, 5%, 22/426) and TRPV1 (s-u, 31%, 36/115) in DRG.  
Green: Atp2a1 FISH, Red: immunostaining of marker genes except MrgA3 FISH.  
Scale bar, 100μm (a-c, g-i), 50μm (d-f, j-u)  
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Figure 12. Atp2a1 is involved in GRPR mediated Ca2+ signaling pathway.  
(a) GRPR-HEK cells cause Ca2+ responses with GRP (250pM). (b) DBHQ (50μM) induces a 
Ca2+ leak from ER by inhibiting Atp2a1 function. Pre-treatment with DBHQ reduced the GRP-
induced Ca2+ responses. (c) GRPR siRNA (60pmol) transfection reduced the GRP Ca2+ 
responses. (d) Atp2a1 knockdown by Atp2a1 siRNA (60pmol) also attenuated the GRP Ca2+ 
responses.  
 
 
 
 
 
 
 
 
 
 
 
 
 
0 30 60 90 120
0.7
0.8
0.9
1.0
1.1
1.2
1.3
1.4
1.5 GRP (250pM)
Time (Sec)
34
0/
38
0
0 30 60 90 120 150 180 210 240
0.8
0.9
1.0
1.1
1.2
1.3
DBHQ (50uM) GRP (250pM)
Time (Sec)
34
0/
38
0
a b 
c d 
 
 
 
 
 
 
 
0 30 60 90 120 150
0
1
2
3
4 GRP (250pM)
Control
GRPR siRNA
Time (Sec)
34
0/
38
0
0 30 60 90 120
0.8
0.9
1.0
1.1
1.2
1.3
1.4
1.5
1.6
1.7 GRP (250pM)
Control
Atp2a1 siRNA
Time (Sec)
34
0/
38
0
 95
 
 
                                                        
                    
 
 
 
 
 
 
                    
 
 
 
 
 
Figure 13. siRNA screening identified novel itch candidate genes.  
(a) 4 histamine-independent genes (Atp2a1, Pld3, Pacsin3, Itpr3) and (b) 3 histamine-dependent  
genes (S100a8, CALR, DSP) were identified. TRPV4 is a both-dependent gene in DRG.  
CQ and histamine were used to verify whether the candidate genes are involved in  
histamine-independent or -dependent itch pathways after siRNA i.t. injections. 
Red: itch genes in the spinal cord, Blue: itch genes in DRG  
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Figure 14. Pld3 is a histamine-independent itch gene in the spinal cord.  
(a) Pld3 siRNA i.t. injection inhibited CQ-induced itch without changing histamine responses 
(***p<0.001, n=4-9). (b-d) siRNA effect was examined by QRT-PCR and ISH. Pld3 siRNA 
decreased Pld3 mRNA levels only in the spinal cord (**p<0.01, n=3). ISH also confirmed the 
decreased level of Pld3 only in the spinal cord. (e) Pld3 expressing spinal neurons overlap with 
GRP+ afferent fibers. Pld3+ DRG cells co-express GRP. GRP immunostaining with 3, 3'-
Diaminobenzidine (DAB) was performed after Pld3 ISH. Arrows represent Pld3-GRP co-
localizations. Blue: ISH, Brown: GRP (f) RT-PCR with LCM dissected spinal cord RNA showed 
that Pld3 is the major Pld isoform expressed in the superficial dorsal horn. Weak expressions of 
Pld2 and Pld4 were also detected. Student t-test was used for statistical analysis. *p<0.05 was 
considered as significantly different. PEI/DEPC-PBS was used as a control for siRNA i.t. injection.  
Scale bar, 100μm (c, e, spinal cord), 50μm (d, e, DRG) 
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Figure 15. Pacsin 3 is a histamine-independent itch gene both in the spinal cord and DRG.  
(a) Pacsin3 siRNA i.t. injection decreased CQ-induced itch (**P<0.01, n=5). (b) Pacsin3 siRNA  
reduced Pacsin3 expressions both in the spinal cord and DRG (*p<0.05, **p<0.01, n=3).  
(c) ISH showed that Pacsin3 is not strongly expressed in the superficial dorsal horn.  
Few Pacsin3+ cells were observed in the superficial dorsal horn. DRG has strong Pacsin3  
expressions in a subset of neuronal populations. Double staining showed that few Pacsin3+ cells  
overlap with GRP+ afferent fibers in the dorsal horn. Pacsin3+ DRG cells co-express GRP.  
Scale bar, 100µm (c, spinal cord), 50µm (c, DRG) 
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Figure 16. Itpr3 is a histamine-independent itch gene in the spinal cord.  
(a) QRT-PCR showed that Itpr3 was the most significantly reduced gene among Itpr genes  
in the bombesin-saporin treated spinal cord suggesting that Itpr3 is co-expressed in GRPR+  
cells. (b) Itpr3 siRNA reduced CQ-induced scratches (***p<0.001, n=5). (c-d) QRT-PCR  
confirmed that Itpr3 siRNA specifically decreased Itpr3 expression in the spinal cord not  
changing the other two isoforms, Itpr1 and 2 (*p<0.05, n=3).  
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Figure 17. Atp2a1 and Itpr3 are involved in GRPR downstream Ca2+ signaling pathway  
for itch. (a) GRP binds to GRPR and activates PLC/IP3 signaling pathways. IP3 binds to  
IP3 receptor on ER membrane and release Ca2+ to intracellular space. Increased Ca2+ can  
activate multiple downstream effector molecules mediating itch transmission. Atp2a1 refills ER  
with Ca2+ by active transport using ATP and maintains Ca2+ concentration gradient. This is  
an important process to make the cell ready to respond to extracellular stimuli. (b) Atp2a1  
inhibition by DBHQ or siRNA impairs the active Ca2+ transport and depletes ER Ca2+ store  
resulting in reduced histamine-independent itch mediated by GRPR. (c) Itpr3 siRNA inhibits  
IP3 receptor directly and blocks Ca2+ release by IP3. Atp2a1 and Itpr3 are crucial downstream  
signaling molecules for GRPR itch signaling pathways.  
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Figure 18. S100a8 is a histamine-dependent itch gene in the spinal cord.  
(a) S100a8 siRNA i.t. injection decreased histamine-induced scratches only (*p<0.05, n=6).  
(b) siRNA reduced S100a8 expression in the spinal cord suggesting that S100a8 is involved  
in histamine itch in the spinal cord (***p<0.001, n=3).  
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Figure 19. CALR is a histamine-dependent itch gene in the spinal cord.  
(a) CALR siRNA reduced histamine-induced itch (***p<0.001, n=5). (b) CALR siRNA  
reduced mRNA levels only in the spinal cord (**p<0.01, n=3). (c) ISH showed spinal cord  
CALR expressions overlapped with GRP stainings. (d) CALR+ neurons co-express GRP in DRG. 
Scale bars, 100µm (c), 50µm (d) 
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Figure 20. DSP is a histamine-dependent itch gene in the spinal cord.  
(a) DSP siRNA decreased histamine-induced scratches (***p<0.001, n=5). (b) DSP siRNA  
reduced mRNA levels in the spinal cord (***p<0.001, n=3).  
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Table 5. QRT-PCR primer sequences 
Gene Primers 
 18sRNA  5’ AAACGGCTACCACATCCAAG        3’ CCTCCAATGGATCCTCGTTA 
 Actin  5’ GGCTGTATTCCCCTCCATCG            3’ CCAGTTGGTAACAATGCCATGT 
 GAPDH  5’ AGGTCGGTGTGAACGGATTTG      3’ TGTAGACCATGTAGTTGAGGTCA 
 GRPR  5’ GGCAGAATTGGCTGCAAACTG      3’ ACAATGGCTTTGTACCTGTCAG 
 NMBR   5’ CTATCGTGAACCCCATGGAC        3’ ATGCATGCTGTGAAACTGCT 
 BRS3  5’ CTTTCGGAGACCTGTTACTTCTG   3’ AGCACTTTACAACCGACCTTTC 
 NK1R  5’ CTCCACCAACACTTCTGAGTC       3’ TCACCACTGTATTGAATGCAGC 
 NMUR2  5’ CAAGCGCAGTGACCTATCCC         3’ GGCATACCTAAGAGCAGGACC 
 Taar7e  5’ CAGGGCATCAGACAGCTACA         3’ ATACACATACGTGGGCGTGA 
 PKR1  5’ GGCTCTGGGTGAGAATACCA         3’ CTTGGCAGCAAAGAAAGTCC 
 P2rx4  5’ CTCGGGTCCTTCCTGTTCG             3’ GTTTCCTGGTAGCCCTTTTCC 
 Atp2a1  5’ TGTTTGTCCTATTTCGGGGTG         3’ AATCCGCACAAGCAGGTCTTC 
 V1rf1  5’ GGTATCACAGACTGTTGCTGG       3’CATTGCTTGTGGAACACCTTTAC 
 Kcnj15  5’ ACCCCGAGTCATGTCAAAGAG       3’ GCTTGTATCGCCACTTCATGT 
 Glp2r  5’ AGGAGACAGTTCAGAAGTGGG      3’ GCCAGCACACGTACTTATCAA 
 Il1r2  5’ CCACTGTGAGCAAATGTCTGT        3’ GCGCCCTTATACCACTGTATC 
 Tlr5  5’ GCAGGATCATGGCATGTCAAC       3’ ATCTGGGTGAGGTTACAGCCT 
 Kcnq2  5’ TACGGGCCAGAGGAACTACG         3’ CAGTCGCAGGACCAGTGAG 
 Cacna1c  5’ ATGAAAACACGAGGATGTACGTT   3’ ACTGACGGTAGAGATGGTTGC 
 Npr1  5’ GCTTGTGCTCTATGCAGATCG        3’ TCGACGAACTCCTGGTGATTTA 
 Nr3c2  5’ CAGACCTTGGAGCGTTCTTC           3’ GCAAAATCCCAGACCGACTA  
 Fpr-rs6  5’ CCAAGATAGGCAGAAGAGGTTTT   3’ TGAAGGAGGCCAGAGTGCTT 
 Klra9  5’ AACTGCAGCAACATGCAAAG          3’ CTGTGTCCCGTGAGGAATCT  
 Tnfrsf7  5’ TCTATAGCCAGCGGTCATCC           3’ AACAAGATTGCACCCAGGAC 
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Figure 21. GRP is expressed in the spinal cord, DRG and skin. (a, b) ISH showed that GRP  
is expressed in neurons of spinal cord dorsal horn. (c, d) GRP is expressed in afferent fivers in  
lamina I. (e, f) GRP is expressed in a small subset of DRG neurons. (g, h) GRP+ free nerve  
endings are innervated into skin. (i, k) GRP+ nerve fibers are co-localized with CGRP suggesting  
that they are peptidergic nerves. Scale bars, 100μm (a-d), 50μm (e-f) 
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Figure 22. GRPR is expressed in the spinal cord, DRG and skin. (a, b) ISH showed that  
GRPR is expressed in spinal cord laminar I and DRG neurons. (c, d) Immunostaining also  
detected GRPR expressions both in the spinal cord and DRG. (e, f) GRPR is expressed in  
skin keratinocytes and dermal mast cells. (g) RT-PCR with skin total RNA confirmed that  
GRPR is expressed in wild type (Wt) but not in GRPR KO skin.  
Scale bars, 100μm (a, c), 50μm (b, d) 
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Figure 23. GRPR is co-expressed with CGRP, IB4 and NF200 in DRG.  
(a-c and j) Majority of GRPR+ cells (61%, 69/114) co-express CGRP. (d-f and k) 33% (46/138) of 
GRPR+ cells are IB4+. (g-i and l) 14% (20/138) of GRPR+ cells overlap with NF200.  
White arrow : co-localization, Scale bar 50μm 
 
 
 
 
 
 
Markers GRPR Merged 
C
G
R
P 
IB
4 
N
F200 
a b c 
d e f 
g h i 
CGRP/GRPR
GRPR+,
CGRP-
GRPR+,
CGRP+
IB4/GRPR
GRPR+, 
IB4-
GRPR+,
IB4+
NF200/GRPR
GRPR+,
NF200-
GRPR+,
NF200+
j k 
61% 
69/114 
33% 
46/138 
l 
14% 
20/138 
 108
 
 
 
 
 
 
 
 
 
 
 
Figure 24. GRP i.d. injection causes itch in mice. (a) GRP induces dose-dependent  
scratching responses by i.d. injection. (b, c) GRP i.d.-induced scratching was abolished  
in GRPR KO mice (***p<0.001, n=6). 
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Figure 25. NMBR, a GRPR homologous receptor, is also expressed in the spinal cord,  
DRG and skin. (a, b) ISH showed NMBR expression in juvenile (1-2 weeks) spinal cord  
dorsal horn. (c) NMBR is expressed in DRG neurons. (d) NMBR expression was observed  
in skin by RT-PCR. Wt : Wild type, KO : GRPR KO, Scale bar, 100μm (a, b), 50μm (c) 
 
 
 
 
 
 
 
 
 
 
 
 
Skin RT-PCR 
1week 2week 
DRG 
a b 
c d 
 110
 
 
Figure 26. Bombesin-like peptide i.d. injection causes itch mediated by peripheral  
GRPR and NMBR. (a) NMB, a GRP homologous peptide induces dose-dependent scratching  
by i.d. injection. (b) NMB i.d.-induced scratching was reduced significantly in GRPR-/- mice  
suggesting that NMB i.d. response is partially dependent of GRPR (*p<0.05, n=4).  
(c-e) All the bombesin-like peptides, GRP, NMB and bombesin i.d. injections causes scratching  
responses that are abolished in NMBR/GRPR-/- (N-/-, G-/-) mice (*p<0.05, **p<0.01, n=4).  
Scratching responses induced by peripheral bombesin-like peptides are mediated by GRPR  
and NMBR.  
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Figure 27. Peripheral applications of GRPR antagonists inhibit CQ and GRP i.d.-induced  
scratches. (a) D-Phe-Leu-bombesin (10nmol) i.p. injection inhibited CQ-induced itch  
(**p<0.01, n=4-6). (b) D-Phe-Leu-bombesin (15nmol) i.d. injection abolished GRP (100nmol) i.d. 
-induced scratches (*p<0.01, n=6). (c) BW-10 (10nmol) i.p. injection reduced CQ-induced itch  
significantly (*p<0.05, n=6). (d) BW-10 (10nmol) i.p. injection decreased GRP i.d.-induced  
scratches (*p<0.05, n=6). (e) NMB i.d.-induced scratches were reduced after D-Phe-Leu 
-Bombesin i.d. injection (*p<0.05, n=6). (f) Histamine itch was also decreased by D-Phe-Leu 
-Bombesin (10nmol) i.p. injection (*p<0.05, n=8). i.p. and i.d. injections were performed 30min  
and 10min before the test, respectively. Saline was used as a vehicle.  
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Figure 28. GRPR antagonist, D-Phe-Leu-bombesin attenuated scratching responses  
significantly in DCP-painted ACD mice model. 1% DCP was painted for sensitization. 0.5%  
DCP was applied again after 7 days to induce ACD. (a) DCP painting causes increased  
epidermal thickness, skin inflammation and robust scratching. (b) D-Phe-Leu-bombesin i.p.  
injection decreased DCP-painted mice scratches. At 14 day, D-Phe-Leu-bombesin (15nmol) was  
i.p. injected 30min before counting scratches (*p<0.05, n=9). Epi: epidermis  
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Figure 29. Specific TRPV4 expression in WT DRG but not in the spinal cord and  
TRPV4-/- DRG. (a) TRPV4 expression in WT DRG. Higher magnification of DRG shown in (b).   
(d) TRPV4 is not expressed in the spinal cord. TRPV4 staining was absent in TRPV4-/- DRG  
(c and f). Scale bar 50μm (a, b, f), 100μm (d) 
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Figure 30. Expression of TRPV4 in DRG neurons. TRPV4 is expressed in about 19% 
(375/1,565) of mouse lumbar DRG neurons. TRPV4 is co-localized with CGRP (61%, 139/227) 
(a-c), GRP (83%, 427/516) (d-f), IB4 (77%, 162/211) (g-i), NF200 (89%, 224/252) (j-l) and TRPV1 
(70%, 196/282) (m-o) Green : Immunostaining of marker genes, Red : TRPV4 fluorescence ISH. 
White arrowheads indicate double-stained cells.  
CGRP: calcitonin gene-related peptide, IB4: isolectin B4, NF200: neurofiliament 200,  
Scale bar 50μm 
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Figure 31. TRPV4 is expressed in both large and small DRG neurons. 
TRPV4 is co-expressed with CGRP (61%, 139/227) (a-c), IB4 (77%, 162/211) (d-f) and  
NF200 (89%, 224/252) (g-i). Green: Immunostaining of various markers, Red: TRPV4 FISH 
signal, White arrowheads: co-localization, Scale bar 50μm  
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Figure 32. TRPV4 is co-expressed in histamine-independent and -dependent pruritic  
genes in DRG. TRPV4 is co-localized with GRP (83%, 427/516) (a-c),MrgprA3 (87%, 62/71) (d-f)  
and H1R (100%, 78/78) (g-i), TRPV1 (70%, 196/282)  (j-l). White arrowheads : co-localization, 
Green : immunostaining of pruritic markers except MrgprA3 FISH, Red : TRPV4 FISH,  
Scale bar 50μm  
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Figure 33. Acute and contact dermatitis-induced chronic itch were reduced in TRPV4  
deficient mice. (a) Acute scratching behaviors induced by intradermal injection of CQ  
(200μg/50μl) and histamine (500μg/50μl) were reduced in TRPV4-/- mice relative to WT littermate 
controls (p<0.001; n=6). (b) TRPV4 siRNA knockdown mice also have defects in both CQ and 
histamine-induced itch compared to control mice injected with DEPC-PBS/PEI (p<0.001, n=6-10). 
(c) qRT-PCR showed that TRPV4 expression was reduced after i.t. injection of siRNA without 
changing TRPV1, TRPV2, TRPA1 and TRPM8 in DRG. (d) TRPV4 expression in DRG was up-
regulated after DNFB treatment without changing other TRP channels, MrgprA3 and H1R (p<0.05, 
n=3). (e) i.t. administration of endogenous TRPV4 agonist, 5, 6-EET (150pmol/5μl) caused 
scratching responses compared to WT littermate controls injected with vehicle (0.1% ethanol) 
(p<0.01, n=6). Scratching behaviors by 5, 6-EET were significantly reduced in TRPV4-/- mice 
versus control WT littermates (p<0.001, n=6). (f) Scratching behavior evoked by DNFB-painting 
was attenuated in TRPV4-/- mice compared to WT controls (p<0.01, n=7). All data are mean ± 
standard error mean (s. e. m.). Error bars represent s. e. m. Student’s t-test (a-d) and Two-way 
ANOVA (e) were used to analyze data significance,  
CQ: chloroquine, WT: wild type, DEPC-PBS: diethylprocarbonate-phosphate buffered saline,  
PEI: polyethylenimine 
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Figure 34. DNFB and AEW-induced scratching behaviors were not inhibited by  
anti-histamine. Saline (control) and 10mg/kg antihistamine (chlorpheniramine) in 10ml saline  
were injected intraperitoneally 30 min before the test. (a) DNFB model  
(n.s., not significant, p=0.1655, n=7) (b) AEW model (n=4-5) 
  
                         
Figure 35.  Dry skin itch is not affected in TRPV4-/- mice. 
AEW-induced dry skin itch is not affected in TRPV4-/- mice compared to WT littermate controls 
(n=7).  
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Figure 36. Repeated DNFB treatment caused an identical allergic contact dermatitis  
in WT and TRPV4-/- mice. (a) Macroscopic picture of DNFB-treated areas on the dorsal skin of  
the WT and TRPV4-/- mice shows a similar dermatitis in these animals including the extent of  
erythema (scale bar: 5mm). (b, c) The systemic manifestations of allergic dermatitis are equally  
present in DNFB-treated WT and TRPV4-/- mice as highlighted by (b) their enlarged spleen and  
lymph nodes (% of body weight), and (c) significantly increased blood neutrophil counts (Absolute  
cell counts (×103/μl), LN: lymph Node, SPL: spleen, WBC: white blood cell, scale bars: 5mm).  
(d) H&E and Toluidine blue staining of the DNFB-treated skin demonstrates a similar degree of  
epidermal hyperplasia, hyperkeratosis, acanthosis, dermal inflammation and mast cell infiltration  
(insets) in WT and TRPV4-/- animals. (scale bar: 50μm). (e) The quantitative analysis confirms 
that the extent of mast cell infiltration in the dermis of WT and TRPV4-/- mice is comparable. The 
bar graphs show the average number of mast cells in 9 random 200X microscope fields. (f) 
Serum IgE levels (μg/ml) are highly elevated and are comparable in DNFB-treated WT and 
TRPV4-/- mice. (g, h) TSLP, a hallmark of allergic skin disease, is equally overexpressed in 
DNFB-treated WT and TRPV4-/- skin as determined by its mRNA levels in the skin. 
Representative pictures are presented; n=6 for each group; p<0.01 compared to the control (i.e. 
Control, WT and TRPV4-/- cohort). Student’s t-test (b-c, e-g), H&E: Hematoxylin and eosin, IgE: 
immunoglobulin E, TSLP: thymic stromal lymphopoietin 
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Figure 37. TRPV4 is involved in neuronal activation of DRG by CQ, histamine and 5, 6-EET.  
DRG neurons increase intracellular Ca2+ responding to CQ (14%, 37/269), histamine (21%, 
57/269) and 5, 6-EET (8%, 22/269). (a) The numbers of CQ (6%, 15/243), histamine (10%, 
24/243) and 5, 6-EET (1%, 3/243) responsive DRG cells were reduced in TRPV4-/- mice DRG 
(**p<0.01 and *p<0.05, n=6). (b) The responding cell populations to CQ (6%, 11/177), histamine 
(15%, 26/177) and 5, 6-EET (3%, 6/177) were reduced in the TRPV4 siRNA-transfected DRG 
culture consistently with the TRPV4-/- DRG (**p<0.01 and *p<0.05, n=6). (c) TRPV4 expression 
was reduced in DRG cells after TRPV4 siRNA transfection (p<0.05, n=3). (d, e) 5, 6-EET caused 
DRG Ca2+ responses in WT DRG neurons but not in the TRPV4-/- DRG. White arrow indicates 5, 
6-EET responding cells with increased intracellular Ca2+. (f) Single cell RT-PCR showed that 5, 6-
EET responding cells express TRPV1 and GRP.  
Student’s t-test (a-c), Scale bar 50μm 
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Figure 38. Potential mechanism of TRPV4-mediated itch pathways. (a) CQ activates 
MrgprA3 and downstream PLC/IP3 Ca2+ signaling pathway. IP3R and SERCA have critical roles 
for intracellular Ca2+ increase. TRPA1 and TRPV4 are involved in CQ-induced itch pathway. 
TRPA1 and TRPV4 may form either homo- or heteromers and increase intracellular Ca2+ through 
membrane Ca2+ influx. Activation of DRG cells will cause a GRP release to stimulate GRPR in 
the spinal cord to transmit itch sensory information. (b) Histamine activates H1R in DRG. H4R 
has been reported to be involved in histamine signaling pathways recently (Rossbach, 
Nassenstein, et. al. 2011). However, detail characterization of H4R-mediated itch pathways in 
DRG have not been done. H1R has multiple downstream signaling pathways. (1) H1R is a GPCR 
and has PLCβ3/IP3/Ca2+ pathway. (2) DAG, the product of PLCβ3-mediated membrane lipid 
hydrolysis, directly activates TRPV1 (Woo, Jung, et. al. 2008). (3) PLA2-AA-HPETE pathway is 
also involved in TRPV1 activation for histamine itch (Kim, Lee et al. 2004). TRPV4 may also 
form heteromers with TRPV1 and regulate histamine itch signaling pathways. Activation of 
histamine-dependent signaling will release neuropeptides such as SP and glutamate. Spinal cord 
NK1Rs or mGluRs can be involved in central itch transmissions. AA : Arachidonic acid, HPETE : 
12-Hydroperoxy-5,8,10,14-eicosatetraenoic acid 
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